<SEC-DOCUMENT>0001144204-18-027214.txt : 20180510
<SEC-HEADER>0001144204-18-027214.hdr.sgml : 20180510
<ACCEPTANCE-DATETIME>20180510172736
ACCESSION NUMBER:		0001144204-18-027214
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180607
FILED AS OF DATE:		20180510
DATE AS OF CHANGE:		20180510
EFFECTIVENESS DATE:		20180510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FENNEC PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		18824177

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709
		BUSINESS PHONE:		(919) 636-4530

	MAIL ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FENNEC PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20140903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADHEREX TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20021223
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tv493448_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities and Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Filed by the
Registrant&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Filed by a
Party other than the Registrant&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">Check the appropriate
box</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Definitive
Proxy Statement</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant
to &sect;240.14a-12</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.55pt; text-align: justify; text-indent: -6.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment of Filing Fee (Check the appropriate
box)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
fee required.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee computed on table below
per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Title of each class of securities to which the transaction applies:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Aggregate number of securities to which the transaction applies:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Per unit price or other underlying value of the transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Proposed Maximum aggregate value of the transaction:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Total fee paid:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee paid previously with
preliminary materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Check box if any part of
the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number, or the Form or Schedule and the date of the filing.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Amount Previously Paid:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Form, Schedule or Registrant Statement No.:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filing Party:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Date Filed:</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF ANNUAL AND SPECIAL MEETING
OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO BE HELD ON JUNE 7, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOTICE IS HEREBY
GIVEN</B> that the annual and special meeting (the &ldquo;<B>Meeting</B>&rdquo;) of the holders of common shares (&ldquo;<B>Common
Shares</B>&rdquo;) in the capital of Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park,
NC, 27709 (&ldquo;<B>Fennec</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo;) will be held at the Omni Hotels &amp; Resorts Berkshire
Place in the Sutton Room, 21E 52<SUP>nd</SUP> Street, New York, New York, USA at 10:00 am EDT on June 7, 2018 for the following
purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">to receive the consolidated financial statements of the Corporation for the year ended December
31, 2017, together with the report of the auditors thereon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">to elect the five directors named in the Management Proxy Circular;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">to appoint auditors and to authorize the directors of the Corporation to fix the auditors&rsquo;
remuneration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">to consider, and, if deemed advisable, approve, with or without modifications, the ordinary resolution
approving the extension of certain outstanding options held by certain of the Corporation&rsquo;s officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">to vote on an advisory (non-binding) vote on executive compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">to transact such further or other business as may properly come before the Meeting or any adjournment
thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Management Proxy Circular
and a form of proxy accompanies this notice, as well as a copy of the Corporation&rsquo;s annual report which contains the consolidated
financial statements of the Corporation for the year ended December 31, 2017, together with the report of the auditors thereon
and management&rsquo;s discussion and analysis of financial condition and results of operations relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors of Fennec has fixed
5:00 p.m. EDT on April 30, 2018 (the &ldquo;<B>Record Date</B>&rdquo;), as the record date for determining the holders of record
of Common Shares who are entitled to receive notice of the Meeting and to attend and vote at the Meeting and any adjournment or
postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholders who are unable to attend
the Meeting in person are requested to date and sign the enclosed form of proxy and return it to Computershare Trust Company of
Canada, 100 University Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy Department in the enclosed envelope, no later
than 10:00 am EDT on June 5, 2018, or if the Meeting is adjourned or postponed, no later than 48 hours (excluding any day which
is not a business day in Toronto) preceding the reconvened Meeting.</B> Proxies may also be deposited with the scrutineers of the
Meeting, to the attention of the Chair of the Meeting, at and immediately prior to the commencement of the Meeting or any adjournments
or postponement thereof. In order to be represented by proxy, you must complete and submit the enclosed form of proxy or other
appropriate form of proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Important Notice Regarding the Availability
of Proxy Materials for the Shareholder Meeting to be held on June 7, 2018:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This Notice, Management Proxy Circular
and the Corporation&rsquo;s Annual Report on Form 10-K are available to you on the Internet at <FONT><U>www.sec.gov</U></FONT>
and <FONT><U>www.sedar.com</U></FONT><U>.</U> We encourage you to access and review all of the important information
contained in these materials before voting. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED at Research Triangle Park, North
Carolina this 30<SUP>th</SUP> day of April, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">By Order of the Board of Directors of Fennec Pharmaceuticals Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/ <B>Khalid Islam</B></I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Khalid Islam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chairman of the Board</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT PROXY CIRCULAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless otherwise stated, information
contained in this management proxy circular (the &ldquo;<B>Circular</B>&rdquo;) is given as of April 30, 2018</I>. <I>Except as
otherwise indicated, all amounts are expressed in United States dollars. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Solicitation and Appointment of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Circular is furnished in connection
with the solicitation of proxies by management of Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle
Park, NC, 27709 (&ldquo;<B>Fennec</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo;) for use at the annual and special meeting
(the &ldquo;<B>Meeting</B>&rdquo;) of the shareholders of Fennec to be held at 10:00 am EDT on June 7, 2018 at the Omni Hotels
&amp; Resorts Berkshire Place in the Sutton Room, 21E 52<SUP>nd</SUP> Street, New York, New York, USA and at any adjournment thereof,
for the purposes set forth in the accompanying notice of annual general and special meeting (the &ldquo;<B>Notice of Meeting</B>&rdquo;).
This Circular was first mailed to shareholders on or about May11, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The persons named in the form of proxy
accompanying this Circular are officers and/or directors of Fennec. A holder of Common Shares (a &ldquo;<B>Shareholder</B>&rdquo;)
has the right to appoint a person, other than the persons named in the form of proxy accompanying this Circular, as nominee to
attend and act for and on behalf of such Shareholder at the Meeting, and may exercise such right by inserting the name of such
person in the blank space provided on the form of proxy, or by executing a proxy in a form similar to the form of proxy accompanying
this Circular. If a Shareholder appoints one of the persons named in the form of proxy accompanying this Circular as the nominee
of the Shareholder and does not direct such nominee to vote either for or against or withhold from voting on a matter or matters
with respect to which an opportunity to specify how the Common Shares registered in the name of such Shareholder are to be voted,
the proxy shall be voted FOR the matter or matters set forth on such proxy and in the discretion of the person appointed on all
other matters (if any) upon which the Shareholder is entitled to cast a vote. A proxy nominee need not be a Shareholder. If the
Shareholder is a corporation, the proxy must be executed by an officer or properly appointed attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for a proxy to be effective at
the Meeting, it must be addressed to the Secretary of Fennec and returned to Computershare Trust Company of Canada, 100 University
Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy Department in the enclosed envelope, not later than 10:00 am EDT on June
5, 2018 or, if the Meeting is adjourned or postponed, not later than 48 hours (excluding any day which is not a business day in
Toronto) before the time of the reconvened Meeting. Proxies may also be deposited with the scrutineers of the Meeting, to the attention
of the Chair of the Meeting, at or immediately prior to the commencement of the Meeting, or any adjournment or postponement thereof.
An undated but executed proxy will be deemed to be dated the date of this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The solicitation of proxies for the Meeting
will be primarily by mail, but proxies may also be solicited personally or by telephone by employees or agents of Fennec. Employees
of Fennec will not receive any extra compensation for such activities. Fennec will pay brokers or other persons holding Common
Shares in their own names, or in the names of nominees, for their reasonable expenses for sending proxies and proxy material to
beneficial owners of Common Shares and requesting authority to execute proxies in respect of such Common Shares. The solicitation
of proxies by this Circular is being made by or on behalf of the management of Fennec and its board of directors (the &ldquo;<B>Board</B>&rdquo;)
and the total cost of this solicitation will be borne by Fennec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only registered shareholders or duly appointed
proxy holders are permitted to vote at the Meeting. The Common Shares represented by a proxy at the Meeting will be voted for or
withheld from voting in each of the election of directors, appointment of auditors and authorizing the Board to fix the auditors
remuneration and advisory vote on executive compensation (together, the &ldquo;<B>Ordinary Matters</B>&rdquo;), and the approval
of the extension of certain outstanding options held by certain of the Corporation&rsquo;s officers (the &ldquo;<B>Special Matter</B>&rdquo;)
in accordance with the instructions of the Shareholder. If no choice is specified in the proxy or the instructions are not certain,
the persons named in the form of proxy accompanying this Circular will vote FOR all of the matters proposed by management at the
Meeting and described in the Notice of Meeting and in the discretion of the person appointed on all other matters (if any) upon
which the Shareholder appointing the proxy is entitled to cast a vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The form of proxy accompanying this Circular,
when properly completed and executed, confers discretionary authority upon the persons named therein with respect to any amendment
or variation to the matters identified in the Notice of Meeting and with respect to other matters which may properly come before
the Meeting. Management of Fennec and the Board knows of no matters to come before the Meeting other than those referred to in
the Notice of Meeting. However, if any other matters (other than the election of directors not currently named in this Circular)
that are not now known to management of Fennec or the Board should properly come before the Meeting, the Common Shares represented
by proxies given in favour of the persons named in the form of proxy accompanying this Circular will be voted on such matters in
accordance with the discretion of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revocation of Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder may revoke a previously given
proxy by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">completing and signing a proxy bearing a later date and depositing it with Computershare Trust
Company of Canada as described above;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">depositing an instrument in writing signed by the Shareholder or an attorney authorized by a document
signed in writing or by electronic signature (if the Shareholder is a corporation, under its corporate seal by an officer or attorney
thereof properly authorized, indicating the capacity under which such officer or attorney is signing), or by transmitting, by telephonic
or electronic means, a revocation signed by electronic signature, or by any other manner permitted by law, which must be received
either (A) with Computershare Trust Company of Canada, 100 University Ave., 8th Floor, Toronto, Ontario M5J 2Y1 attention Proxy
Department in the enclosed envelope, not later than 10:00 am EDT on June 5, 2018, or (B) with the scrutineers of the Meeting to
the attention of the Chair of the Meeting on the day of the Meeting, or any adjournment thereof, prior to the taking of the vote
to which such proxy relates; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">in any other manner permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advice to Beneficial Holders of Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This section applies to beneficial holders
of Common Shares who are not registered holders. The information set forth in this section is of significant importance to many
holders of Common Shares, as a substantial number of Shareholders do not hold Common Shares in their own name.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice of Meeting, the proxy and this
Circular are being sent to both registered and non-registered owners of Common Shares. Only registered holders of Common Shares,
or the persons that they appoint as proxies, are permitted to attend and vote at the Meeting. In many cases, Common Shares are
beneficially owned by a shareholder and are registered in the name of an intermediary such as a bank, broker or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has distributed copies
of the Notice of Meeting, the proxy and this Circular (collectively, the &ldquo;<B>Meeting Materials</B>&rdquo;) to all of the
intermediaries for delivery to beneficial holders. Intermediaries are required to forward the Meeting Materials to beneficial holders
unless a beneficial holder has waived the right to receive them. This permits beneficial holders to direct the voting of the Common
Shares that they beneficially own. If a beneficial holder wishes to attend and vote at the Meeting in person (or have another person
attend and vote on behalf of the beneficial holder), the beneficial holder should strike out the names of the persons named in
the proxy and insert the beneficial holder&rsquo;s (or such other person&rsquo;s) name in the blank space provided. In any case,
beneficial holders should carefully follow the instructions of the intermediaries, including those regarding when and where the
proxy or proxy authorization form is to be delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Record Date and Entitlement to Vote</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Record Date for the purpose of determining
Shareholders entitled to receive the Circular and to vote at the Meeting has been fixed as 5:00 p.m. EDT on April 30, 2018 (the
&ldquo;<B>Record Date</B>&rdquo;). Each Shareholder at the close of business (5:00 p.m. EDT) on the Record Date is entitled to
attend the Meeting in person or by proxy and to cast one (1) vote for each Common Share held by such Shareholder on the Record
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Corporation&rsquo;s articles,
the quorum for the transaction of business at any meeting of Shareholders shall be two or more persons present in person or represented
by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Securities and Principal Holders
of Voting Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at April 30, 2018, there were 18,489,603
Common Shares issued and outstanding. Each Common Share carries the right to one vote at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership of the Common Shares
in the following table is determined in accordance with the rules and regulations of the U.S. Securities Exchange Commission (the
&ldquo;<B>SEC</B>&rdquo;). Under these rules, a person is deemed to beneficially own a Common Share if that person has or shares
voting power or investment power with respect to that share, or has the right to acquire beneficial ownership of that share within
60 days, including through the exercise of any option, warrant or other right or the conversion or any other security. Shares issuable
under stock options and warrants are deemed outstanding for computing the percentage of the person holding options or warrants
but are not outstanding for computing the percentage of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at April 30, 2018, the directors and
Named Executive Officers (defined below under &ldquo;Executive Compensation&ndash;Summary Compensation Table&rdquo;) of Fennec
and, to the knowledge of the directors and Named Executive Officers of Fennec, after reasonable enquiry, their respective associates,
as a group, beneficially owned, directly or indirectly, or exercised control or direction over 40,740 Common Shares (approximately
0.22% of all outstanding Common Shares on such date) and options and warrants to purchase 1,981,820 Common Shares (approximately
10.72% of the aggregate of all outstanding Common Shares on such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the number
of Common Shares beneficially owned as of April 30, 2018 by: (1) each director and Named Executive Officer; (2) all directors and
Named Executive Officers as a group; and (3) each person known by us to own 5 percent or more of the outstanding Common Shares.
The percentage of beneficial ownership for the following table is based upon 18,489,603 Common Shares outstanding as of April 30,
2018. Except as indicated below, the security holders listed possess sole voting and investment power with respect to the shares
beneficially owned by that person. The address for each listed shareholder who is a director or a Named Executive Officer is c/o
Fennec Pharmaceuticals Inc., PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common Share <BR> Options Exercisable <BR>
Within 60 Days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common Share <BR> Purchase Warrants <BR> Exercisable Within <BR> 60 Days</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total Stock and </B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Stock Based </B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Holdings<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>% </B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Ownership<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: justify">Adrian J. Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">173,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">173,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.93</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dr. Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Chris A. Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.71</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Rostislav Raykov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">866,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">906,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.68</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">All Officers and Directors as a Group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,981,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,022,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.88</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Southpoint Capital Advisors, LP.<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,997,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,997,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.62</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Essetifin SpA<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,225,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,225,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.45</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Manchester Management Company, LLC.<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">959,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">999,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,959,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.06</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">venBio Select Advisor, LLC.<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,022,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,105,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.95</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">683 Capital Management, LLC.<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">867,185</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">971,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.22</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify">For purposes of this table &ldquo;beneficial ownership&rdquo;
is determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, pursuant to which a person or group of
persons is deemed to have &ldquo;beneficial ownership&rdquo; of any Common Shares that such person or group has the right to acquire
within 60 days after April 30, 2018. For purposes of computing the percentage of outstanding Common Shares held by each person
or group of persons named above, any shares that such person or group has the right to acquire within 60 days after April 30,
2018 are deemed outstanding but are not deemed to be outstanding for purposes of computing the percentage ownership of any other
person or group. As of April 30, 2018 there were 18,489,603 Common Shares issued and outstanding.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify">Southpoint Capital Advisors, LP, 623 Fifth Avenue, Suite
2503, New York, New York 10022. John S. Clark, II holds dispositive power over the shares owned by Southpoint Capital Advisors,
LP.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Essetifin SpA, Via Sudafrica
20, Rome, Italy 00144. Mario Artali holds dispositive power over the shares by Essetifin SpA.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Manchester Management Company,
LLC, 131 Charles Street, 1<SUP>st</SUP> Floor, Boston Massachusetts 02114. Includes 1,250,000 shares owned by Manchester Explorer,
L.P. and 416,666 shares owned by JEB Partners, L.P. Manchester Management holds dispositive power over the shares held by Manchester
Explorer, L.P. and JEB Partners, L.P. Jeb Besser and Morgan Frank hold shared dispositive power over the shares held by Manchester
Management Company, LLC. Additionally, Jeb Besser owns 126,633 shares for which he has sole dispositive power and Morgan Frank
owns 166,666 shares for which he has sole dispositive power.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">venBio Select Advisor,
LLC, 120 West 45<SUP>th</SUP> Street, Suite 2802, New York, NY 10036. Behzad Aghazadeh holds dispositive power over the shares
owned by venBio Select Advisor, LLC.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">683 Capital Management,
LLC, 595 Madison Avenue, 17th Floor, New York, New York 10025. Ari Zweiman holds dispositive power over the shares owned by 683
Capital Management, LLC.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approval Requirements and Eligible Voting
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Ordinary Matters and Special
Matter must be approved by a simple majority of the votes cast by Shareholders, present in person or by proxy at the Meeting. For
these purposes, any spoiled votes, illegible votes, defective votes, abstentions, and broker non-votes will not be considered votes
cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the Ordinary Matters and Special
Matter discussed elsewhere in this Circular, management of Fennec does not intend to present and does not have any reason to believe
that others will present, at the Meeting, any item of business other than those set forth in this Circular. If, however, any other
business is properly presented at the Meeting and may properly be considered and acted upon, proxies will be voted by those named
in the applicable form of proxy in their sole discretion, including with respect to any amendments or variations to the matters
identified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORDINARY MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Presentation of Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audited financial statements of the
Corporation for the fiscal year ended December 31, 2017, together with the report of the auditors thereon, will be placed before
the Meeting. Shareholders who wish to be added to the mailing list for the annual financial statements and Management&rsquo;s Discussion
and Analysis should complete the appropriate sections of the proxy or contact the undersigned at PO Box 13628, 68 TW Alexander
Drive, Research Triangle Park, North Carolina 27709 Attention: Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of directors of Fennec to be
elected at the Meeting is five (5). The following are the names of the persons for whom it is intended that votes will be cast
for their election as directors of the Corporation pursuant to the proxy which is hereby solicited, unless the Shareholder directs
therein otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dr. Khalid Islam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. Adrian Haigh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. Chris A. Rallis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. Marco Brughera</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mr. Rostislav Raykov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of office for each such person
will be until Fennec&rsquo;s next annual meeting of Shareholders or until such person&rsquo;s successor is elected or duly appointed.
<B>In the event that prior to the Meeting any vacancies occur in the slate of nominees submitted above, it is intended that discretionary
authority shall be exercised to vote the proxy hereby solicited (unless otherwise directed as aforesaid) for the election of any
other person or persons as directors. Fennec management is not now aware that any of such nominees would be unwilling to serve
as a director if elected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Board unanimously recommends that
Shareholders vote FOR the election of the above-named director nominees. The persons named in the enclosed form of proxy will vote
FOR the election of each of the director nominees to hold office until the close of the next annual meeting of Shareholders, unless
a Shareholder has specified in the proxy that his or her Common Shares are to be withheld from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec has adopted a majority voting policy
in director elections that will apply at any meeting of Shareholders where an uncontested election of directors is held. Pursuant
to this policy, if the number of proxy votes withheld for a particular director nominee is greater than the votes for such director,
the director nominee will be required to submit his or her resignation as a director to the Chair of the Board promptly following
the applicable Shareholders&rsquo; meeting. Following receipt of resignation, the Governance and Nominating Committee will consider
whether or not to accept the offer of resignation and make a recommendation to the Board. Within 90 days following the applicable
Shareholders&rsquo; meeting, the Board shall publicly disclose in a news release their decision whether to accept the applicable
director&rsquo;s resignation or not, including the reasons for rejecting the resignation, if applicable. The Board shall accept
the resignation absent exceptional circumstances. A director who tenders his or her resignation pursuant to this policy will not
be permitted to participate in any meeting of the Board or the Governance and Nominating Committee at which the resignation is
considered. A copy of the majority voting policy may be found on the Fennec website at <FONT><U>www.fennecpharma.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the name
of each of our executive officers and directors, such person&rsquo;s principal occupation or employment, all other positions with
Fennec and any significant affiliate thereof now held by such person, if any, the year in which such person became a director of
Fennec and such person&rsquo;s age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has an Audit Committee,
a Compensation Committee, and a Governance and Nominating Committee. The current members of such committees are noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name and Province/State and <BR> Country of Residence, Position</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Current Principal Occupation and <BR> Principal Occupation for Previous <BR> Five Years</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Director <BR> Since</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common <BR> Shares<BR>
 Held</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Options to <BR> Acquire <BR> Common <BR> Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 31%; text-align: justify">Robert Andrade, Texas USA<BR> Chief Financial Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: justify">CFO of Fennec Pharmaceuticals; previously senior analyst Magnetar Capital; previously Portfolio Manager Millennium Partners</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">N/A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">516,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Chris A. Rallis, North Carolina, USA<BR> Director<SUP>(1)(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Executive in-residence at Pappas Ventures; previously, CEO of ImmunoBiosciences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Rostislav Raykov, New Jersey, USA<BR> Chief Executive Officer, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">CEO of Fennec Pharmaceuticals Inc.; previously Portfolio Manager Alchem Partners; previously Portfolio Manager John Levin &amp; Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">July 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">866,010</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Marco Brughera, Milano, Italy <BR> Director<SUP>(2)(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">CEO of Leadiant Biosciences SpA; previously Global Head Rare Disease and R&amp;D at Sigma-tau; VP Preclinical Development at Nerviano Medical Sciences.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,545</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Adrian J. Haigh, Dublin, Ireland<BR> Director<SUP>(1)(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Senior Vice President and General Manager of EMEA Region at PTC Therapeutics; previously Chief Operating Officer at Gentium GmbH; previously Regional VP Commercial Operations at Biogen Idec</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Khalid Islam, Zug, Switzerland<BR> Chairman of Board, Director<SUP>(1)(2)(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Founder/co-founder of Sirius Healthcare Partners GMbH; previously Chairman and CEO of Gentium S.p.A.; previously CEO of Arpida AG</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,825</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Member of the Audit Committee</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Member of the Compensation Committee</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Member of the Governance and Nominating Committee</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Robert Andrade</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Andrade has served as Chief Financial
Officer since November 2015. Mr. Andrade was previously Chief Financial Officer and Director of Fennec from September 2009 until
August 2013. In addition to his role with Fennec, Mr. Andrade was a private investor in 2015, and a senior analyst at Magnetar
Capital from 2013 - 2014. Mr. Andrade graduated from University of Southern California, where he earned a Masters of Arts degree
and Bachelor of Arts degree in economics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Chris A. Rallis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rallis has&nbsp;served as&nbsp;a director
of Fennec since August 2011. Mr. Rallis has been an executive-in-residence at Pappas Ventures, a life&nbsp;science venture capital
firm since January 2008.&nbsp;Previously, Mr. Rallis was the&nbsp;President and Chief Executive Officer of ImmunoBiosciences, Inc.
(&ldquo;IBI&rdquo;), a vaccine&nbsp;technology company formerly located in Raleigh, North Carolina from April 2006 through June
2007.&nbsp;Prior to joining IBI, Mr. Rallis served as an executive in residence (part-time) for Pappas Ventures,&nbsp;and as a
consultant for Duke University and Panacos Pharmaceuticals, Inc.&nbsp;Mr. Rallis is the former President&nbsp;and Chief Operating
Officer (&ldquo;COO&rdquo;) and director of Triangle Pharmaceuticals, Inc.,&nbsp;which was acquired by Gilead Sciences in January
2003 for approximately $465&nbsp;million.&nbsp;Prior to assuming the role of President and COO in March 2000, he was&nbsp;Executive
Vice President, Business Development and General Counsel. While at&nbsp;Triangle, Mr. Rallis&nbsp;participated in 11 equity financings
generating gross proceeds&nbsp;of approximately $500 million.&nbsp;He was also primarily responsible for all business&nbsp;development
activities which included a worldwide alliance with Abbott&nbsp;Laboratories and the in-licensing of ten compounds. Before joining
Triangle in&nbsp;1995, Mr. Rallis served in&nbsp;various business development and legal management roles with Burroughs Wellcome
Co. over a 13-year period, including Vice President of Strategic Planning&nbsp;and Business Development. Mr. Rallis also&nbsp;serves
on the boards of Aeolus Pharmaceuticals, a biopharmaceutical company&nbsp;located in Mission Viejo, California and Tenax Therapeutics,
Inc., a biopharmaceutical company located in Morrisville, North Carolina.&nbsp;Mr. Rallis received his A.B. degree in&nbsp;economics
from Harvard College and a J.D. from Duke University. As a result of these and other professional experiences, Mr. Rallis possesses
particular healthcare industry knowledge and experience which strengthens the Board&rsquo;s collective qualifications, skills,
and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rostislav Raykov</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Raykov has served as a director of
Fennec since July 2009 and as Chief Executive Officer since July 2009.&nbsp;From January 2006 to December 2007, Mr. Raykov was
a portfolio manager for Alchem Investment Partners and John Levin &amp; Co. Prior to founding Alchem, Mr. Raykov was a portfolio
manager and securities analyst for John A. Levin &amp; Co. Event Driven Fund (2002-2005). Prior to joining John A. Levin &amp;
Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking
analyst at Bear Stearns (1998-1999).&nbsp;&nbsp;Mr. Raykov earned a B.S. in Business Administration from the University of North
Carolina at Chapel Hill. As a result of these and other professional experiences, Mr. Raykov has financial expertise and experience
with the Corporation as it has developed within the drug development industry and, as such, is able to provide the Corporation
with unique insight and guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Marco Brughera</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January 2011, Dr. Brughera has been
CEO of Lediant Biosciences SpA and has held several positions for the Sigma-Tau Group, including CEO and Global Head of Sigma Tau
Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals.&nbsp;He drove the commercial revival
of a lead oncology product line resulting in its successful sale for a total of around $900M.&nbsp;He also successfully out-licensed
the Defibrotide US rights to Jazz Pharmaceuticals. From 2004 to 2010, Dr. Brughera served as the Vice President of Preclinical
Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company.&nbsp;He
also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group.&nbsp;From 1999
to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior
to 1999, he held various positions at Pharmacia &amp; Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company.
He currently serves on the Board of Solgenix and Lee&rsquo;s Pharmaceutical and until early 2014 was a member of the Board of Gentium
SpA.&nbsp;Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist
Mr. Brughera has wide-spread experience and knowledge of pharmaceutical drug development in international companies. His knowledge
in particular, of clinical drug development in Europe, deepens the Board&rsquo;s collective qualifications, skills and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Adrian J. Haigh </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Adrian Haigh has been Senior Vice President
and General Manager of EMEA Region and Asia Pacific at PTC Therapeutics, Inc. since September 2014. Previously Mr. Haigh served
as Senior Vice President, Commercial Operations and Chief Operating Officer of Gentium GmbH since March 2011. Prior to joining
Gentium, Mr. Haigh served as Regional Vice President, Commercial Operations at Biogen Idec where he managed several affiliates&nbsp;and
also the global distributor business and prior to that was the General Manager of Amgen Nordis and Portugal. He served as the Executive
Vice President of Global Marketing and Corporate Planning at EUSA Pharma and joined EUSA from Amgen where he led the international
oncology franchise. Mr. Haigh previously&nbsp;has held senior commercial and marketing positions at SmithKline Beecham, Schering
Plough, Organon and Novo Nordisk. He has been a Director of Fennec Pharmaceuticals Inc. since April 28, 2014 and a Director at
Arch Biopartners Inc. since August 21, 2014. He received a Bachelor of Arts with Honors in Economic History from Huddersfield Polytechnic,
West Yorkshire, England and a Diploma in Marketing from the Institute of Marketing. As a result of these and other professional
experiences, Mr. Haigh has extensive international oncology development expertise which strengthens the Board&rsquo;s collective
qualifications, skills and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dr. Khalid Islam</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Khalid Islam was the Chairman and CEO
of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and
profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1
billion merger with Jazz Pharmaceuticals, plc. Subsequent to the sale of Gentium, Dr. Islam has been involved from both an advisory
and board level in several public and private healthcare related companies. From 1999-2008, Dr. Islam was President and CEO of
Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons.
From 1987-1999, he held various positions in HMR &amp; MMD (now Sanofi-Aventis). From 1977-1987, Dr. Islam worked in academia at
Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea
College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80
articles in leading journals. He is an advisor to the venture group Kurma Biofund (Paris). He is a founder/co-founder of Sirius
Healthcare Partners GmbH (Zurich), PrevAbr LLC (D.C.), BioAim LLC (L.A.) &amp; Life Sciences Management GmbH (Zug). Dr. Islam is
Board Chair at Minoryx Therapeutics (Spain). He serves on the board of Karolinska Development (Sweden), MolMed S.p.A. (Italy) and
Immunomedics Inc. (IMMU) all of which are traded publicly, and the private company OxThera (Sweden). In the past, he has served
as Chairman of the Board of Directors of Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo). Dr. Islam&rsquo;s
extensive international pharmaceutical expertise in transitioning companies from development to production strengthens the Board&rsquo;s
collective qualifications, skills and experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Appointment of Auditors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2017, the Corporation appointed
Haskell &amp; White LLP as the Corporation&rsquo;s auditors. Shareholders will be asked to vote for the appointment of Haskell
&amp; White LLP as auditors of the Corporation, to hold office until the next annual meeting of Shareholders of the Corporation
or until a successor is duly elected or appointed, at a remuneration to be fixed by the Board of Directors. Approval of the ordinary
resolution requires the affirmative vote of a majority of the votes cast in respect thereof by holders of Common Shares represented
at the Meeting. The person designated in the enclosed form of proxy intends to vote FOR the appointment of Haskell &amp; White
LLP as auditors of the Corporation, unless instructed otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Board unanimously recommends that
Shareholders vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation at the Meeting. The persons named
in the enclosed form of proxy will vote FOR the appointment of Haskell &amp; White LLP as auditors of the Corporation until the
end of the next annual meeting of the Shareholders and the authorization of the directors to fix their remuneration, unless a Shareholder
has specified in the proxy that his or her Common Shares are to be withheld from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisory Vote on Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Dodd-Frank Wall Street Reform and Consumer
Protection Act of 2010 enables the Corporation&rsquo;s Shareholders to vote to approve, on an advisory or non-binding basis, the
compensation of our named executive officers as disclosed in this Circular in accordance with SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For information on the Corporation&rsquo;s
executive compensation programs and how they reflect the Compensation Committee&rsquo;s philosophy and are linked to the Corporation&rsquo;s
performance, see &ldquo;Compensation Discussion and Analysis&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are asking for Shareholder approval
of the compensation of our named executive officers as disclosed in this Circular in accordance with SEC rules, which disclosures
include the disclosures under &ldquo;Compensation Discussion and Analysis&rdquo;, the compensation tables and the narrative discussion
following the compensation tables. This vote is not intended to address any specific item of compensation, but rather the overall
compensation of our named executive officers and the policies and practices described in this Circular (the &ldquo;<B>Advisory
Vote on Executive Compensation Resolution</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This vote is advisory and therefore not
binding on the Corporation, the Board or the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is the text of the advisory
vote on executive Compensation resolution to be considered at the Meeting (the &ldquo;<B>Advisory Executive Compensation Resolution</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">RESOLVED, that the
compensation paid to the Corporation&rsquo;s named executive officers, as disclosed in this Circular pursuant to Item 402 of Regulation
S-K, including the &ldquo;Compensation Discussion and Analysis&rdquo;, the compensation tables and narrative discussion be, and
hereby is, APPROVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Board unanimously recommends that
Shareholders vote FOR the Advisory Executive Compensation Resolution. The persons named in the enclosed form of proxy will vote
FOR the Advisory Executive Compensation Resolution, unless a Shareholder has specified in the proxy that his or her Common Shares
are to be withheld from voting in respect thereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL MATTER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendments to Executive Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation wishes to extend certain
options held by its executive officers, employees and consultants. The rules of the TSX require that any extension of the term
options benefitting an insider and any extension of options where the exercise price of such options is below the current market
price be approved by shareholders pursuant to Section 613(i)ii) of the TSX Company Manual. In addition, NASDAQ Listing Rule 5635(c)
requires that any material amendment to a stock option be approved by shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Andrade, the Corporation&rsquo;s
Chief Financial Officer, holds options that are scheduled to expire as listed in the table below, and it is proposed that the
expiry date of such options be extended. Further, the table below details the options proposed to be extended. The extension of
Mr. Andrade&rsquo;s options is intended to avoid further dilution caused by new grants following the expiry of such options in
accordance with their terms. Accordingly, the Corporation&rsquo;s shareholders are being asked to approve extension of the options
held by Mr. Andrade in the manner set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strike Price</B></FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market Price <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>% Discount <SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current<BR>
Expiry Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amended<BR>
Expiry Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/18/2010</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,961</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD$2.43</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD$15.84</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85%</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/13/2018</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/18/2020</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In respect of options where the strike
price is denominated in USD, this represents the </FONT>closing price of the Corporation&rsquo;s common shares on Nasdaq on the
Record Date. <FONT STYLE="font-family: Times New Roman, Times, Serif">In respect of options where the strike price is denominated
in CAD, this represents the </FONT>closing price of the Corporation&rsquo;s common shares on the Toronto Stock Exchange on the
Record Date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents percentage discount of the strike price included in the table above to the market price.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Raykov, the Corporation&rsquo;s Chief
Executive Officer, also holds options that are scheduled to expire as listed in the table below, and it is proposed that the expiry
date of such options be extended in a manner consistent with Mr. Andrade&rsquo;s options referred to above. Further, the table
below details the options proposed to be extended. Similarly, the extension of Mr. Raykov&rsquo;s options is intended to avoid
further dilution caused by new grants following the expiry of such options in accordance with their terms. Accordingly, the Corporation&rsquo;s
shareholders are being asked to approve extension of the options held by Mr. Raykov in the manner set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amended</B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grant Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Strike Price</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Market Price <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>% Discount <SUP>(2)</SUP></B></P></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2010</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">323,961</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CAD$2.43</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CAD$15.84</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85%</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2020</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In respect of options where the strike
price is denominated in USD, this represents the </FONT>closing price of the Corporation&rsquo;s common shares on Nasdaq on the
Record Date. <FONT STYLE="font-family: Times New Roman, Times, Serif">In respect of options where the strike price is denominated
in CAD, this represents the </FONT>closing price of the Corporation&rsquo;s common shares on the Toronto Stock Exchange on the
Record Date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents percentage discount of the strike price included in the table above to the market price.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is proposed that a total of 647,922
options be extended as described above, which represents 3.5% of the Corporation&rsquo;s issued and outstanding Common Shares
as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resolution in respect of the foregoing
proposed option extensions (the &ldquo;<B>Option Extension Resolution</B>&rdquo;) must be approved by a&nbsp;simple majority of
the votes cast by the Shareholders voting in person or by proxy at the Meeting, other than the votes attaching to the 40,740 Common
Shares beneficially held by Mr. Raykov (which represents 0.22% of the issued and outstanding Common Shares as of the date hereof).
Mr. Andrade does not beneficially own any Common Shares. <B>Unless otherwise directed, it is the intention of the management designees
to vote proxies in the accompanying form in favor of the Option Extension Resolution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is the text of the Option
Extension Resolution to be considered at the Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;BE IT RESOLVED AS AN ORDINARY RESOLUTION
THAT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The following changes to
the expiry dates of the options granted to Mr. Robert Andrade under the Corporation&rsquo;s Amended and Restated Stock Option
Plan are hereby approved:</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 24%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 17%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 18%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amended</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Employee</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grant Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt"><B>Strike Price</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Robert Andrade</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2010</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">323,961</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">CAD$2.43</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">08/13/2018</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2020</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0in; text-align: left">2.</TD><TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">The
following changes to the expiry dates of the options granted to Mr. Rostislav Raykov under the Corporation&rsquo;s Amended and
Restated Stock Option Plan are hereby approved:</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amended</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Employee</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grant Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Strike Price</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiry Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rostislav Raykov</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2010</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">323,961</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">CAD$2.43</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">08/18/2020</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0in; text-align: left">3.</TD><TD STYLE="text-align: justify">Any director or officer of the Corporation is hereby
authorized for and on behalf of the Corporation to take all actions and to execute all documents as may be desirable to give effect
to this resolution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE COMPENSATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion relates to the Named Executive
Officers listed in the Summary Compensation Table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mandate of the Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is the task of the Compensation Committee
to periodically review Fennec&rsquo;s compensation structure with respect to its Named Executive Officers, including its Chief
Executive Officer, to ensure that Fennec continues to attract and retain qualified and experienced individuals to its management
team and to motivate these individuals to perform to the best of their ability and in Fennec&rsquo;s best interests. The Compensation
Committee determines the compensation of the Named Executive Officers, evaluates and approves the compensation plans, policies
and programs of the Corporation and recommends to the Board from time to time other incentive compensation plans that it determines
should be considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In reviewing executive compensation,
the Compensation Committee relies on the advice of the Chief Executive Officer regarding other executive officers and allows him
to participate in the Committee&rsquo;s deliberations on those executive officers. The Chief Executive Officer, however, is not
allowed to participate in the Committee&rsquo;s deliberations on his compensation. The Compensation Committee may not delegate
any of its responsibilities to another entity or to an individual without the approval of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General Compensation Philosophy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key components of executive officer
compensation are salaries, cash incentive awards and stock options. Fennec&rsquo;s policy with respect to the compensation of
Named Executive Officers is to establish annual goals with respect to corporate development and the individual areas of responsibility
of each Named Executive Officers and then to review total compensation with respect to the achievement of these goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Salary and Non-Equity Incentive Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is Fennec&rsquo;s policy that the base
salaries paid to its Named Executive Officers reflect, in addition to the criteria set out above, the individual&rsquo;s responsibility,
experience and achievements. Each year the Compensation Committee sets a series of objectives for each executive and for the executive
team as a whole to determine the opportunity for cash incentive awards. These objectives are prioritized and assigned potential
values in light of overall company objectives, including with respect to scientific, clinical, regulatory, intellectual property,
business and corporate development, and financial objectives. The Compensation Committee reviews both base salaries and cash incentive
awards on at least an annual basis to ensure that the relevant criteria are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The annual compensation considerations
also include the awarding of stock options. The granting of options to the Named Executive Officers under the Corporation&rsquo;s
Amended and Restated Stock Option Plan, as amended from time to time (the &ldquo;<B>Stock Option Plan</B>&rdquo;) serves three
primary purposes: (1) to recognize significant performance during the past year; (2) to provide long-term incentives for future
efforts, since the value of the options is directly dependent on the market valuation of the Corporation; and (3) to retain individuals,
as the options typically vest over time. When determining whether and how many new option grants will be made, the Compensation
Committee takes into account the amount and terms of any outstanding options. The Compensation Committee generally considers the
granting of options twice annually to all eligible employees, including executive officers. The Committee, in its discretion, may
grant options at other times during a fiscal year to a Named Executive Officer for performance or other reasons. Fennec does not
require its Named Executive Officers to own a specific number of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Analysis of Named Executive Officer
Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee is charged with
annually reviewing and approving corporate goals and objectives relevant to each of the Named Executive Officer&rsquo;s compensation,
evaluating each officer&rsquo;s performance in light of those goals and objectives, and fixing and determining each Named Executive
Officer&rsquo;s level of salary and award of cash incentive payments and options based on this evaluation. In determining the long-term
incentive component of each Named Executive Officer&rsquo;s compensation, the Compensation Committee considers the Corporation&rsquo;s
performance and relative shareholder return, the value of similar incentive awards to other similarly situated executive officers
at companies in the comparator group, the awards given to the Named Executive Officer in past years, and such other factors as
the Compensation Committee considers relevant. Specifically, the Compensation Committee&rsquo;s review and evaluation includes
measurement of the following areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the achievement of corporate objectives, such as financings, partnerships and other business development,
and consideration of those achievements in light of budgetary constraints and other challenges facing the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Corporation&rsquo;s financial condition;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Corporation&rsquo;s share price and market capitalization; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the advancement of our product candidates, both preclinical and clinical.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee has reviewed
and discussed the Compensation Discussion and Analysis contained in this Circular with management and, based on that review and
discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included
in this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Submitted by:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE
COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Marco Brughera,
Chair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Chris Rallis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Khalid Islam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee Interlocks and
Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marco Brughera, Chris Rallis and Khalid
Islam are the current members of the Compensation Committee. None of these individuals was at any time during 2017 or at any other
time an officer or employee of ours. No interlocking relationship exists between any member of our Compensation Committee and any
member of any other company&rsquo;s board of directors or compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has determined that each member
of the Compensation Committee is &ldquo;independent&rdquo; under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets out certain information
respecting the compensation paid for the fiscal years ended December 31, 2017, December 31, 2016 and December 31, 2015 to our Chief
Executive Officer and to our Chief Financial Officer, who were the only executives officer whose compensation exceeded $100,000
for the fiscal year ended December 31, 2017 (collectively, the &ldquo;<B>Named Executive Officers</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Name and Principal Position</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Year</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Salary (USD$)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Bonus (USD$)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><B>Option Awards </B><BR> <B>(USD$)<SUP>(1)</SUP></B></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total (USD$)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: justify">Rostislav Raykov, CEO</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">2017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">262,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">160,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">187,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">610,079</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Robert Andrade, CFO<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,788</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,791</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Represents the aggregate grant date fair value computed in accordance
with FASB ASC Topic 718.&nbsp;Dollar value amounts are based on individual grants to each of, Mr. Raykov and Mr. Andrade of 150,000,
100,000 and 75,000, 50,000 options, respectively, on July 5, 2016 and June 27, 2017, at an exercise price of $2.45 and $5.10 per
common share, respectively, and will expire on July 5, 2023 and June 27, 2024, respectively. One-third of these options shall vest
as of grant the grant date and be exercisable one year after the grant date (the &ldquo;Vesting Commencement Date&rdquo;). The
remaining two-thirds of the options shall vest monthly at a rate of 1/36<SUP>th</SUP> of the remaining grant and shall be exercisable
as of the last day of each following month after the Vesting Commencement Date. As of the third anniversary of the grant date,
all of the options shall be vested.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Mr. Andrade served as the Chief Financial Officer of Fennec from September 2009 until August 2013.
He re-joined as the Corporation&rsquo;s Chief financial officer in November 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rostislav Raykov </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Raykov has been employed by Fennec
since July 2009.&nbsp;Pursuant to an employment agreement dated May 3, 2010 between Mr.&nbsp;Raykov and Fennec, Mr. Raykov is employed
as Fennec&rsquo;s Chief Executive Officer and: (a) received an initial annual salary in the amount of $140,000, subject to annual
adjustment by our Board of Directors, (b) upon approval by shareholders of our amended stock option plan was granted options to
purchase up to 5.0% of our common shares estimated by us to be outstanding upon completion of the 2010 Rights Offering, and (c)
may receive annual bonuses at the sole discretion of the Board.&nbsp;If Mr. Raykov&rsquo;s employment terminates due to a change
of control of Fennec, Mr. Raykov&rsquo;s remaining unvested options shall immediately vest and be fully exercisable. If Mr.&nbsp;Raykov
is dismissed from employment by us for any reason other than &ldquo;for cause,&rdquo; we are obligated to pay Mr. Raykov severance
compensation equal to twelve months of salary ($275,000 per year at December 31, 2017). The initial term of the agreement was for
one year and the agreement automatically extends for additional one-year periods unless terminated by either party in accordance
with the agreement. Effective January 1, 2018, Mr. Raykov&rsquo;s salary was increased to $350,000 per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Robert Andrade </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Andrade has been employed by Fennec
since November 2015. Mr. Andrade is employed as Fennec&rsquo;s Chief Financial Officer.&nbsp;Pursuant to an employment agreement
dated November 13, 2015, Mr. Andrade (a) receives an initial annual salary in the amount of $165,000, and (b) may receive annual
bonuses at the sole discretion of the Board.&nbsp;In addition, conditioned upon the approval of Fennec's shareholders, Fennec will
extend Mr. Andrade's existing options to their original expiry date of seven years from issuance. If Mr. Andrade&rsquo;s employment
terminates due to a change of control of the Fennec, Mr. Andrade&rsquo;s remaining unvested options shall immediately vest and
be fully exercisable. If Mr. Andrade is dismissed from employment by us for any reason other than &ldquo;for cause,&rdquo; we are
obligated to pay Mr. Andrade severance compensation equal to six months of salary ($200,000 per year at December 31, 2017). Effective
January 1, 2018, Mr. Andrade&rsquo;s salary was increased to $250,000 per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to their employment agreements,
Mr. Raykov and Mr. Andrade, are a party to a confidentiality and intellectual property agreement with the Corporation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the employment agreements for each of
Mr. Andrade and Mr. Raykov &ldquo;for cause&rdquo; is generally defined as (1) material breach of the terms of the employment or
intellectual property agreements; (2) failure to perform the duties inherent in the Employee&rsquo;s position in good faith and
in a reasonable and appropriate manner; or (3) acts of fraud or embezzlement or other intentional misconduct which adversely affects
the Corporation's business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payments on Termination </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides details regarding
the estimated incremental payments from the Corporation to each of the current Named Executive Officers assuming termination without
cause on December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Severance <SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Estimated Bonus</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Value of benefits</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Rostislav Raykov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Chief Executive Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">275,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: windowtext">(1)</FONT></TD><TD STYLE="text-align: justify">Severance payments are calculated based on the annualized salary and short term incentives described
herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payments on Change of Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides details regarding
the estimated incremental payments from the Corporation to each of the current Executive Officers upon change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Change of Control <BR> Multiple</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated Bonus<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Value of benefits</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Rostislav Raykov</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2 X</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">637,499</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.25 X</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">301,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: windowtext">(1)</FONT></TD><TD STYLE="text-align: justify">Change of control payments are calculated based on the two-year annualized average salary plus
cash bonus as calculated as of December 31, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the payments above, an incentive
plan has been established pursuant to which, upon completion of a change in control transaction, 1% of the transaction value (up
to a maximum of $2,000,000) be set aside and paid to key personnel upon completion of such change in control transaction, with
50% of such incentive pool being payable to the CEO and the balance to other key personnel as determined by the CEO in consultation
with the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Grants, Exercises and Holdings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
concerning the number and value of unexercised options held by each Named Executive Officer as of December 31, 2017. All executive
awards, with the exception of those expiring 6/27/2024 and 07/05/2023, vest and are exercisable immediately. The current Stock
Option Plan provides for grants denominated in US and CAD dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: justify; padding-left: 0.125in">Rostislav Raykov</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">5.10</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,833</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.45</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">07/05/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.69</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">12/31/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1.59</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">01/24/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">0.72</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/23/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1.05</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/20/2019</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CAD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1.89</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CAD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.43</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5.10</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.45</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">07/05/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CAD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1.89</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CAD$</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.43</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/18/2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Incentive Plan Awards &ndash;
Value Vested or Earned During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table details the value of
executive options on the vesting date that vested during 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of Options <BR> Vested During Year</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option-Based Awards</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value Vested During the Year </B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(USD$)<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Non-Equity Incentive Plan <BR> Compensation &ndash; Value Earned <BR> During the Year (USD$)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Rostislav Raykov</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">58,334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">199,048</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Robert Andrade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">87,499</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">298,562</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The value of the vested option-based
awards represents the aggregate dollar value that would have been realized if the options under the option-based award had been
exercised on the vesting date. The dollar value was computed by determining the difference between the closing market price of
the Common Shares on the Nasdaq at the deemed exercise on the vesting date and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Termination Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of his termination with us
other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment of $275,000 as of December 31, 2017.
In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment
of $100,000 as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the compensation
earned by the Corporation's non-executive directors for the year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Fees paid in <BR> Cash</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Stock Awards</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><B>Option Awards<SUP>(1)(2)</SUP></B></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Dr. Islam</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">89,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">522,710</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">611,710</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Mr. Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,452</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,952</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Mr. Haigh</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">498,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Mr. Rallis</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">49,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">98,452</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">147,452</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">223,500</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,217,711</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,441,211</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.4pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.4pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD STYLE="text-align: justify">Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.4pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD STYLE="text-align: justify">Detail of grants are presented in the following table:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date of Grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options Granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Exercise Price $USD</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 61%; text-align: justify">Mr. Rallis</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">June 27, 2017</FONT></TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">20,000</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">5.10</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Mr. Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 27, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Mr. Haigh</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 27, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dr. Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 27, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: justify">Mr. Haigh</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 25, 2014<SUP>(1)</SUP></FONT></TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">66,666</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">2.31</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Dr. Islam</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">April 25, 2014<SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,666</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2.31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">218,332</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Original grant was for 133,333 options to each of Mr. Haigh and Dr. Islam. The grant&rsquo;s conditional vesting clause could be satisfied by the Corporation obtaining either orphan drug designation in the EU or Pediatric Use Marketing Authorization status for PEDMARK<SUP>TM</SUP>. On March 7, 2017, the Corporation received notice that PUMA status had been achieved by Medicine &amp; Healthcare products Regulatory Agency (MHRA). The ruling of the MHRA was reviewed by the Compensation Committee of the Board of Directors on August 10, 2017 and the board voted to vest the remaining portion of the original grants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Grants, Exercises and Holdings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
concerning the number and value of unexercised options held by each Named Executive Officer as of December 31, 2017. All executive
awards vest and are exercisable immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Outstanding Equity Awards at
December 31, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Underlying&nbsp;Unexercised<BR> Options&nbsp;(#)&nbsp;Exercisable</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Exercise&nbsp;Price&nbsp;(USD$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Expiration&nbsp;<BR> Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Value
    of </B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Unexercised in-</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>the-Money<BR>

    Options (USD$)<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Adrian Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">133,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">04/25/2021</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,027,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/31/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/09/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Chris Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11/18/2019</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">04/04/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">05/17/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,775</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">08/17/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,332</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11/20/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,715</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">04/03/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">05/17/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,036</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">08/13/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,184</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">08/23/2020</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">01/24/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">04/25/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">05/15/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,917</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">08/04/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,956</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11/07/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,641</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/31/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">03/16/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">05/11/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,127</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">08/03/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,314</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11/10/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/09/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,728</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">04/25/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,027,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/31/2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/11/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/09/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,329</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12/30/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">281,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">06/27/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Calculated using the closing price of the Corporation&rsquo;s common shares on December 29, 2017
USD$10.02 on the Nasdaq which was the last trading day for the year 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Incentive Plan Awards &ndash;
Value Vested During the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table details the value of
director options on the vesting date that vested during 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of Options <BR> Vested During Year</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><B>Option-Based Awards</B><BR> <B>Value Vested During the Year </B><BR> <B>(USD$)<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Non-Equity Incentive Plan <BR> Compensation &ndash; Value Earned <BR> During the Year (USD$)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Adrian Haigh</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">86,666</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">282,664</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chris Rallis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Khalid Islam</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,664</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marco Brughera</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">218,824</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">565,328</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The value of the vested option-based
awards represents the aggregate dollar value that would have been realized if the options under the option-based award had been
exercised on the vesting date. The dollar value was computed by determining the difference between the closing market price of
the Common Shares on the OTC at the deemed exercise on the vesting date and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The annual compensation considerations
for non-executive directors also include the awarding of stock options. We believe that granting of options to the non-executive
directors serves three primary purposes: (1) to recognize the significant time and effort commitments during the past year; (2)
to provide long-term incentives for future efforts since the value of the options is directly dependent on the market valuation
of the Corporation; and (3) to retain quality individuals. When determining whether and how many new option grants will be made,
the Compensation Committee takes into account the amount and terms of any outstanding options. Fennec does not require its non-executive
directors to own a specific number of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each non-management member receives an
annual base retainer of $30,000. The Chairman of the Board shall receive an additional annual fee of $50,000 and includes all activities
of the Chairman. The Chair of the Audit Committee receives an additional annual fee of $7,500. Chair of any other Committee shall
receive an additional annual fee of $5,000. These annual base retainer and annual cash fees are to be paid quarterly and are in
lieu of any per-meeting fees. Board members shall also be reimbursed for any out of pocket disbursements for attending Board or
Committee meetings or any other meeting at the Corporation&rsquo;s request. Certain non-management directors are entitled to additional
fees of US$2,000 per month, plus US$1,000 per attended meeting in connection with committee membership and meeting attendance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Stock Option Plan as last ratified
by Shareholders on June 8, 2016 was adopted to develop the interest and incentive of eligible employees, directors and other service
providers of the Corporation in the Corporation's growth and development by giving eligible Participants (as defined below) an
opportunity to purchase Common Shares on a favourable basis, thereby advancing the interests of the Corporation, enhancing the
value of the Common Shares for the benefit of all Shareholders and increasing the ability of the Corporation to attract and retain
skilled and motivated individuals in the service of the Corporation. The maximum number of Common Shares that may be issued under
the Stock Option Plan is a rolling maximum equal to 25% of the issued and outstanding Common Shares from time to time (as of April
30, 2018, this maximum percentage equals 4,622,401 Common Shares). As of April 30, 2018 options for an aggregate of 2,506,964 Common
Shares have been granted and remain issued and outstanding under the Stock Option Plan (representing approximately 14% of the currently
issued and outstanding Common Shares), options for 296,135 Common Shares have been exercised under the Stock Option Plan (representing
approximately 1.6% of the currently issued and outstanding Common Shares) since June 27, 2017, and the Stock Option Plan has 2,115,437
unallocated options (representing approximately 11.4% of the currently issued and outstanding Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within the above aggregate limit of 25%
of the issued and the issued and outstanding Common Shares from time to time, the Stock Option Plan contains no limits on the number
or percentage of such options that may be granted to insiders of the Corporation or to any one person. The Board currently has
the right, in its sole discretion, to alter, amend or discontinue the Stock Option Plan from time to time and at any time. However,
no such amendment or discontinuation may alter or impair the rights or increase the obligations under the Stock Option Plan of
Participants without the consent of the Participants. Further, any amendment to the Stock Option Plan is subject to prior regulatory
approval. The Stock Option Plan&rsquo;s amending procedures explicitly provide that shareholder approval is not required to implement
any amendments, save and except for amendments related to (i) the maximum number of Common Shares or any other shares of the Corporation
which are reserved for issuance under the Stock Option Plan (and under any other share compensation arrangement of the Corporation);
(ii) a reduction in the exercise price for options held by insiders; and (iii) an extension to the term of options held by insiders.
Examples of the amendments that may be made by the Board without shareholder approval include, without limitation, amendments related
to (a) the vesting provisions of the Stock Option Plan or any option granted under the Stock Option Plan, (b) the early termination
provisions of the Stock Option Plan or any option granted under the Stock Option Plan, (c) the addition of any form of financial
assistance by the Corporation for the acquisition by all or certain categories of Participants, and the subsequent amendment of
any such provision which is more favourable to such Participants, (d) the addition or modification of a cashless exercise feature,
payable in cash or Common shares, which provides for a full deduction of the number of underlying Common Shares from the Stock
Option Plan reserve, (e) changing the maximum percentage of Common Shares which are reserved for issuance under the Stock Option
Plan to a maximum number of Common Shares not exceeding the number of Common Shares which then represents the maximum percentage
previously approved by the Corporation&rsquo;s security holders; (f) the suspension or termination under applicable laws (including,
without limitation, the rules, regulations and policies of the TSX); and/or (g) general housekeeping matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participation in the Stock Option Plan
shall be limited to directors, employees and service providers who are designated from time to time by the Compensation Committee
(each, a &ldquo;<B>Participant</B>&rdquo;). Board nominees or other associates or affiliates of the Corporation&rsquo;s largest
shareholder, Southpoint Capital Advisors, are not eligible to participate in the Stock Option Plan. Subject to the terms of the
Stock Option Plan, the Compensation Committee determines the Participants designated to participate in the Stock Option Plan, the
number of Common Shares such Participant is entitled to purchase and the price at which the Common Shares may be purchased and
the applicable vesting period. The option price at which the Common Shares may be purchased under the Stock Option Plan is the
fair market value of the Common Shares of the Corporation at the time of grant, which under the Stock Option Plan is the closing
price of the Common Shares on the TSX or NASDAQ Stock Market on the trading day immediately preceding the date of grant (if the
Common Shares are then listed on the TSX or NASDAQ Stock Market).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options granted under the Stock Option
Plan must be exercised within a period of seven (7) years from the date of grant, failing which the Participant's right to purchase
such Common Shares lapses. The Stock Option Plan provides that should the expiry date of any vested stock option of a Stock Option
Plan participant fall on, or within nine (9) trading days immediately following, a Black-Out Period, the expiry date of such a
vested stock option will automatically be the date that is ten (10) trading days from the date the relevant Black-Out Period ends.
Unless otherwise determined by the Compensation Committee and specifically set forth in the stock option agreement executed by
the Participant, options vest and may be exercised by the Participant as to one-third on each of the first, second and third anniversaries
of the date of grant. The Compensation Committee may, however, in its sole discretion by written notice to any Participant, accelerate
the vesting of all or any of the options of a Participant. The Participant's rights under the options granted under the Stock Option
Plan are not assignable or transferable by the Participant. The Corporation does not currently have any arrangements in place for
financial assistance to facilitate the purchase of securities by Participants under the Stock Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Participant&rsquo;s right to exercise
options ceases following any of the following events (each of which, a &ldquo;<B>Participant Termination Date</B>&rdquo;): (i)
if an employee, such Participant&rsquo;s employment with the Corporation or any of its subsidiaries is terminated for any reason;
(ii) if a director, such Participant ceases to be a director on the Board for any reason; or (iii) if a service provider, such
Participant ceases to provide services to the Corporation. In such case, the Participant, or the Participant's legal representative,
as the case may be, may only exercise such options that are then vested any time prior to the earlier of: the original expiry date
of such option, or within 30 days of the Participant Termination Date, or if specifically approved by the Board, such later date
which may not be more than three (3) years following the Participant Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For U.S. federal income tax purposes, an
optionee who is granted an incentive stock option under the Stock Option Plan will generally not recognize taxable income either
at the time the option is granted or upon its exercise, although the exercise will increase the optionee&rsquo;s alternative minimum
taxable income by an amount equal to the difference, if any, between the fair market value of the shares at the time of exercise
and the option's exercise price, and therefore may subject the optionee to the alternative minimum tax. Upon the sale or exchange
of the shares more than two years after grant of the option and more than one year after exercising the option, any gain or loss
will be treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee will recognize ordinary
income at the time of sale or exchange equal to the difference between the exercise price and the lower of (i) the fair market
value of the shares at the date of the option&rsquo;s exercise or (ii) the sale price of the shares. Fennec will be entitled to
a deduction in the same amount as the ordinary income recognized by the optionee. Any gain or loss recognized on such a premature
disposition of the shares in excess of the amount treated as ordinary income will be characterized as long-term or short-term capital
gain or loss, depending on the optionee&rsquo;s holding period with respect to such shares. Options that do not qualify as incentive
stock options under the Stock Option Plan are referred to as nonstatutory options. Generally, an optionee will not recognize any
taxable income at the time he or she is granted a nonstatutory option. Upon its exercise, however, the optionee will generally
recognize taxable ordinary income measured as the excess of the then fair market value of the shares acquired over the exercise
price of the option. Any taxable income recognized in connection with an option exercise by an optionee who is also one of our
employees will be subject to tax withholding by us. Fennec will be entitled to a tax deduction in the same amount as the ordinary
income recognized by the optionee with respect to shares acquired upon exercise of a nonstatutory option. Upon resale of such shares
by the optionee, any difference between the sales price received and the fair market value for the shares on the date of exercise
of the option will be treated as long-term or short-term capital gain or loss, depending on the optionee&rsquo;s holding period
with respect to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Stock Option Burn-Rate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets out information
with respect to the burn-rate calculations for the Stock Option Plan as at December 31, 2017, 2016 and 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 75%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Percentage</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Burn Rate</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">The total number of options issued in 2017 divided by the weighted average number of outstanding Common Shares for 2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.27%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">The total number of options issued in 2016 divided by the weighted average number of outstanding Common Shares for 2016</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2.90%</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">The total number of options issued in 2015 divided by the weighted average number of outstanding Common Shares for 2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">0.65%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors&rsquo; and Officers&rsquo;
Liability Insurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec has liability insurance for its
directors and officers. The aggregate annual premium for that insurance is approximately $115,430 no part of which is payable
by the directors and officers of the Corporation. The insurance coverage under the policy for each loss is limited to an annual
aggregate of $2,500,000 for each policy year. Total limits provided (under both primary and excess policies) total $7,500,000,
with an additional $2,500,000 applicable solely to Side A (non-indemnifiable claim(s)). The policy is subject to a $250,000 retention
for any non-securities claim, $750,000 for securities claims and $1,500,000 for merger objection suits and there shall be no retention
for any non-indemnifiable claim(s) made against a director or officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indebtedness of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 13(k) of the Securities Exchange
Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), prohibits Fennec from making or arranging an extension of credit
to its directors or executive officers in the form of a personal loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No individual, who is or was a director,
executive officer or employee of Fennec, nor any proposed nominee for election as a director of Fennec, nor any associate of any
one of them:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is or, at any time since the beginning of Fennec&rsquo;s most recent completed financial period,
has been indebted to Fennec or any of its subsidiaries; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">was indebted to another entity, which indebtedness is, or was at any time during Fennec&rsquo;s
most recent completed financial period, the subject of a guarantee, support agreement, letter of credit or other similar arrangement
or understanding provided by Fennec or any of its subsidiaries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Interest of Informed Persons in Material
Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the BCBCA and our articles,
directors who have a material interest in any person who is a party to a material contract or a proposed material contract with
Fennec are required to disclose that interest and abstain from voting on any resolution to approve that contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of Fennec, except as disclosed
below, no informed person or proposed nominee for election as a director of Fennec and no associate or affiliate of the foregoing
persons has or has had any material interest, direct or indirect, in any transaction since the commencement of Fennec&rsquo;s last
completed financial period or in any proposed transaction which has materially affected or would materially affect Fennec or any
of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with regulations of the SEC,
Fennec must disclose in this Circular any transaction or series of transactions in Fennec&rsquo;s last two completed fiscal years
to which Fennec was a party and in which any director or executive officer of Fennec, or any of their immediate family members
had a direct or indirect material interest, if the amount involved exceeds the lesser of $120,000 or one (1) percent of the average
of the Corporation&rsquo;s total assets at year end for the last two completed fiscal years (a &ldquo;<B>Related Party Transaction</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Performance Graph</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following line graph compares the percentage change, from December 31, 2012 to December 31, 2017, in cumulative total shareholder
return for $100 (CAD$ for TSX and US$ for AMEX) invested in our </FONT>Common Shares <FONT STYLE="font-family: Times New Roman, Times, Serif">with
cumulative total return of the AMEX Composite, the AMEX Biotechnology Index and the S&amp;P/TSX Composite Total Return Index. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="tv493448_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides certain information
with respect to securities authorized for issuance under equity incentive plans as of December 31, 2017 (share amounts are in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Plan Category</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)<BR> Number&nbsp;of&nbsp;securities&nbsp;to&nbsp;<BR> be issued<BR> upon&nbsp;exercise&nbsp;of&nbsp;outstanding<BR> options&nbsp;warrants&nbsp;and&nbsp;rights&nbsp;(*)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)<BR> Weighted<BR> average&nbsp;exercise&nbsp;price&nbsp;of<BR> outstanding&nbsp;options,&nbsp;warrants&nbsp; <BR> and rights</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(c)<BR> Number&nbsp;of&nbsp;securities&nbsp;remaining<BR> available&nbsp;for&nbsp;future&nbsp;issuance&nbsp;under<BR> equity&nbsp;compensation&nbsp;plans<BR> (excluding&nbsp;securities&nbsp;reflected&nbsp;in<BR> Column&nbsp;(a))</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 61%; text-align: justify">Equity compensation plan <BR> approved by shareholders</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">2,315</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">&nbsp;<BR><FONT STYLE="font-size: 10pt">USD $ 2.45</FONT></TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 10%; text-align: right">2,288</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,315</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,288</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* <FONT STYLE="font-family: Times New Roman, Times, Serif">The
Corporation&rsquo;s current stock option plans allow for the issuance of stock options denominated in both U.S. dollars and Canadian
dollars.&nbsp;This table presents the number and weighted-average exercise price of outstanding options by the currency associated
with the original grants.&nbsp;At December 31, 2017 we had 1,603 stock options denominated in U.S. dollars with a weighted-average
exercise price of $2.70 and 712 stock options denominated in CAD dollars with a weighted-average exercise price of CAD$2.38.&nbsp;There
were a total of 2,315 stock options outstanding with a combined weighted-average exercise price of USD$2.45 (Canadian denominated
exercise prices were converted using the December 31, 2017 exchange rate of 0.7966 CAD/USD. At December 31, 2017, we had 2,288
stock options available for future issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT ON CORPORATE GOVERNANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec believes that good corporate governance
is important to ensure that Fennec is managed for the long-term benefit of its shareholders. In connection with Fennec&rsquo;s
commitment to comply with the standards of applicable securities legislation, Fennec has continued to review Fennec&rsquo;s corporate
governance practices and policies and has compared them to developing practices and regulation in Canada and the United States.
In particular, Fennec has considered developing rules and guidelines for corporate governance practices and policies, and related
disclosures, promulgated by the Canadian Securities Administrators, the SEC as well as the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec&rsquo;s Board has adopted a Mandate
of the Board of Directors, Corporate Governance Guidelines and a Code of Business Conduct and Ethics applicable to all officers,
directors and employees of Fennec. The Board has also (i) restated the charter of the Audit Committee, (ii) established a separate
Governance and Nominating Committee and adopted a written charter for the committee, (iii) restated the charter of the Compensation
Committee, and (iv) appointed an Independent Chairman of the Board. Each of the various committee charters and other corporate
governance documents are regularly reviewed with a view to determining if any updates are necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set out below is a description of certain
corporate governance practices of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders who wish to communicate with
members of the Board of Directors, including the independent directors individually or as a group, may send correspondence to them
care of the Chief Executive at our principal executive offices. Such communication will be forwarded to the intended recipient(s).
Fennec currently does not intend to have the Chief Executive screen this correspondence, but it may change this policy if directed
by the Board due to the nature or volume of the correspondence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors is composed of a
majority of independent directors. The Board applies the definition of independence found in Canadian National Instrument 58-101
and National Policy 58-201. The Board has determined that four of the current five directors are &ldquo;independent&rdquo;, being
Messrs. Rallis, Brughera, Haigh and Islam. Only one director has a material relationship with the Corporation and are therefore
is not independent. Mr. Raykov, Chief Executive Officer of the Corporation is considered to have a material relationship with the
Corporation by virtue of his executive officer position. Fennec is of the view that the composition of its Board reflects a diversity
of background and experience that are important for effective corporate governance. Other directorships held by Board members are
described in this Circular under the heading &ldquo;Ordinary Matters &ndash; Election of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the financial year ended December
31, 2017, the Board devoted a portion of six meetings to discuss in the absence of directors who are not &ldquo;independent,&rdquo;
and certain of the Committees also conducted executive sessions where all participants were independent directors. In order to
facilitate open and candid discussion among its independent directors, the Corporate Governance Guidelines provide that independent
directors should meet at least annually without the presence of management or non-independent directors, that the Chairman or Lead
Independent Director is authorized to call additional meetings of the independent directors and that the Chairman or Lead Independent
Director is authorized to act as the presiding director at such meetings and to develop the agenda for such meetings. In addition,
each Board member is free to suggest the inclusion of items on any Board or Committee meeting agenda and suggest pre-meeting materials
to either the Chair of the Board or the Lead Independent Director. At any meeting of the Board, each Board member is also free
to raise subjects that are not on the agenda for that meeting. Furthermore, each Board committee, the Chairman and the Lead Independent
Director, on behalf of the independent directors as a group, have the authority to hire legal, accounting, financial or other advisors
as they may deem necessary in their best judgment, without the need to obtain the prior approval of any officer of the Corporation.
The Chief Financial Officer of the Corporation will arrange for payment of the invoices of any such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Directors&rsquo; Attendance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended December 31,
2017, the Board met on twelve occasions, the Audit Committee met on five occasions, the Compensation Committee met on five occasions,
and the Governance and Nominating Committee met on five occasions. The following table sets forth the attendance of directors at
meetings of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 53%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Director</B></FONT></TD>
    <TD NOWRAP STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 37%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Attendance at</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Board Meetings</B></FONT></TD>
    <TD NOWRAP STYLE="width: 5%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Adrian Haigh</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">12/12</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chris Rallis</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">12/12</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Khalid Islam</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/12</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Marco Brughera</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/12</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board expects management to be responsible
for the day-to-day operations of and to implement the approved strategic business plan within the context of authorized budgets
and corporate policies and procedures. Management is expected to report regularly to the Board in a comprehensive, accurate, and
timely fashion on Fennec&rsquo;s business and affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec does not have a formal written policy
regarding attendance of Board members at annual meetings of the shareholders. Fennec, however, strongly encourages all directors
to attend such meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mandate of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has the overall responsibility
for the strategic planning and general management of Fennec&rsquo;s business and affairs. In fulfilling its responsibilities, the
Board is responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adoption of a strategic plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of the annual operating and capital expenditure budgets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">identification of the principal risks of the business and ensuring the implementation of the appropriate
systems to manage these risks;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">succession planning, including appointing and monitoring senior management;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adoption of a communications policy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">approval of acquisitions, dispositions, investments and financings that exceed certain prescribed
limits;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">integrity of the internal control and management information systems; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">development of clear position descriptions for directors, including the Chair of the Board, the
Chair of each Board committee and, together with the CEO, a clear position description for the CEO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board discharges its responsibilities
directly and through committees that have specific areas of responsibility. The frequency of Board meetings and the nature of items
discussed during the meetings depend on the opportunities or risks that Fennec faces. The Board, directly and through its committees,
has adopted a process whereby it assesses the risk factors that must be identified and managed to ensure Fennec&rsquo;s long-term
viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board mandate generally describes the
Board&rsquo;s expectation of management and provides a list of specific matters for which management must obtain Board approval
prior to implementation. The Board mandate also provides that the Board annually establish performance objectives for the CEO,
which responsibility has been delegated to the Compensation Committee. In addition, the Board receives regular updates from management
concerning the Corporation&rsquo;s progress toward achieving corporate goals. The Board has also delegated to the Compensation
Committee responsibility for evaluating the CEO&rsquo;s compensation, which evaluation includes review of the CEO&rsquo;s performance
against annual performance objectives for the year and input from the Chairman, Lead Independent Director as well as other directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board Mandate is attached as Schedule
&ldquo;A-1&rdquo; to this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Position Descriptions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board Mandate and the Governance and
Nominating Committee Charter provide that the Board is responsible for the development of clear position descriptions for directors,
including the Chair of the Board and the chair of each board committee; and, together with the Chief Executive Officer, a clear
position description for the Chief Executive Officer, which includes delineating management&rsquo;s responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2015, Khalid Islam was elected
Chairman of the Board. The Board determined that in the best interest of the Corporation the most effective leadership structure
at this time is to separate the roles of Chairman and Chief Executive Officer. As an independent director, Dr. Islam is responsible
for overseeing and ensuring the independence of and separation between management and the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors has an active role,
as a whole and also at the committee level, in overseeing the identification and management of our principal risks. The Board of
Directors regularly receives reports from senior management on areas of material risk to our Corporation<B>, </B>including our
credit, liquidity, operational, legal and regulatory risks. In carrying out its responsibilities under its charter, the Audit Committee
reviews our major financial risk exposures and the steps management has taken to monitor and control such exposures, and it also
meets periodically with management to discuss policies with respect to risk assessment and risk management. In addition, the Compensation
Committee oversees the management of risks relating to our executive and non-executive compensation plans and arrangements, and
the Governance and Nominating Committee manages risks associated with the independence of the Board of Directors and potential
conflicts of interest. While each committee oversees certain risks and the management of such risks, the entire Board of Directors
is regularly informed through committee reports about such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ethical Business Conduct</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2004, Fennec&rsquo;s Board
adopted a Mandate of the Board of Directors, Corporate Governance Guidelines and a Code of Business Conduct and Ethics (the &ldquo;<B>Code</B>&rdquo;)
applicable to all officers, directors and employees of Fennec. You can access the Code in the corporate governance section of Fennec&rsquo;s
website at <FONT><B><U>www.fennecpharma.com</U></B></FONT><B>. </B>Fennec undertakes to provide any person
without charge, upon request, a copy of such code by writing to Attn: Code of Ethics Request, Fennec Pharmaceuticals Inc., 68 TW
Alexander Drive, PO Box 13628, Research Triangle Park, North Carolina 27709<FONT STYLE="font-variant: small-caps">. </FONT>Fennec
is committed to adhering to applicable legal requirements and maintaining the highest standards of conduct and integrity. The Code
is intended to promote those goals in conjunction with the Corporation&rsquo;s Insider Trading Policy, Disclosure Policy and Audit
Committee Complaint Procedures. The Code sets out the legal and ethical standards of conduct for personnel of Fennec and addresses
topics such as: reporting obligations and procedures; honest and ethical conduct and conflicts of interest; compliance with applicable
laws and Corporation policies and procedures; confidentiality of corporate information; use of corporate assets and opportunities;
public disclosure and books and records; and non-retaliation. The Board is not aware of any conduct of a director or officer that
constitutes a departure from the Code and, as a result, since the beginning of Fennec&rsquo;s fiscal year ended December 31, 2017,
there have been no material change reports filed that pertain to such a departure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Code provides that the Governance and
Nominating Committee shall monitor and periodically evaluate compliance with the Code and its application to the Corporation&rsquo;s
business. In addition, the Code sets out the procedures adopted by the Audit Committee for the receipt, retention and treatment
of complaints and concerns regarding accounting, internal accounting control, or auditing matters. In each case, the Code provides
that the Corporation will not discipline, discriminate against or retaliate against any employee who reports a complaint or concern
in good faith, whether or not the information is ultimately proven to be correct, or who cooperates in any investigation or inquiry
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to ensure independent judgment
in considering transactions or agreements in which a director or officer has a material interest, the Code contains a process that
must be followed regarding the disclosure, consultation and approval of transactions involving potential conflicts of interest.
As a first step, officers and directors must disclose such matters to the Chief Executive Officer and to the Chair or any other
disinterested member of the Governance and Nominating Committee charged with reviewing conflicts of interest. The Board has adopted
rules for what activities constitute conflicts of interest and potential conflicts of interest, as well as procedures for determining
whether a relationship or transaction constitutes a conflict of interest, the current versions of which are attached as appendices
to the Code. Following disclosure, any officer or director must avoid or terminate any activity that involves an actual or reasonably
apparent conflict of interest unless it is determined at the appropriate level that the activity is not a conflict of interest
or is otherwise not harmful to the Corporation or improper. Disinterested members of the Governance and Nominating Committee shall
make any such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the BCBCA and our articles,
directors who have a material interest in any person who is a party to a material contract or a proposed material contract with
us are required to disclose that interest and abstain from voting on any resolution to approve that contract. In addition, no director,
director nominee or officer may enter into any transaction or relationship that is disclosable by such person or the Corporation
pursuant to the BCBCA or by the Corporation pursuant to SEC rules without the prior approval of the disinterested members of the
Governance and Nominating Committees, and no such person may directly or indirectly approve, or represent the Corporation or the
other party in arranging, the terms of any transaction between the Corporation and a party with which he/she has any relationship
of a type that is disclosable by such person or the Corporation pursuant to the BCBCA or by the Corporation pursuant to SEC rules.
All transactions between the Corporation and a party with which a director, officer or employee has such a relationship shall be
on an arm&rsquo;s length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Orientation and Continuing Education</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Responsibility for the oversight of orientation
for new directors and continuing education programs for all directors with respect to the Corporation&rsquo;s business and financial
matters, corporate governance and other appropriate subjects is assigned to the Governance and Nominating Committee under its charter.
In this regard, the Governance and Nominating Committee&rsquo;s duties include ensuring the adequacy of the orientation and education
program for new members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee
is also responsible for arranging continuing education for directors in order to ensure that directors maintain the skill and knowledge
necessary to meet their obligations as directors. Given the Corporation&rsquo;s limited resources, to date, no formal external
continuing education programs have been sponsored by the Corporation but members of the Board are free to attend such programs
as they determine necessary and in the Corporation&rsquo;s best interest. The Corporation also provides directors with the opportunity
to meet with senior management of the Corporation, including the Chief Financial Officer, as well as external advisors, at any
time and such personnel and advisers are regularly invited to present at Board meetings or in connection with Board retreats to
provide updates in legal, accounting, governance and other business developments. Some meetings are held at the Corporation&rsquo;s
premises, allowing directors the opportunity to gain additional insight into the Corporation&rsquo;s operations. In addition, analyst
reports and other information relating to the Corporation&rsquo;s business and the industry in which it operates are presented
at Board meetings and strategy sessions and industry-related articles of interest are distributed to Board members from time to
time. Pursuant to each Committee charter, directors are permitted to obtain advice and assistance from internal or external advisors,
including for the purposes of continuing education and developments relevant to board responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nomination of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has a nominating committee as
part of the Governance and Nominating Committee that is charged with identifying individuals qualified to become Board members.
The Governance and Nominating Committee also recommends to the Board (a) the director nominees for the next annual meeting of shareholders
and candidates to fill vacancies on the Board and (b) the directors to be appointed to Board Committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of its mandate, the Governance
and Nominating Committee (i) develops criteria for selecting directors and, when appropriate, conducts searches for prospective
Board members whose skills and attributes meet those criteria, (ii) considers nominees submitted to the Board by shareholders if
appropriate biographical and background information is provided, applying the same criteria and following substantially the same
process in considering candidates suggested by shareholders as it does in considering other candidates and (iii) prior to recommending
a nominee for election, determines that the election of the nominee as a director would effectively further the policies set forth
in the Corporation&rsquo;s corporate governance guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with its mandate to review
and recommend to the Board the directors to be appointed to the various committees of the Board and the Chair of each committee,
the Governance and Nominating Committee considers the desired qualifications for membership on each committee, the availability
of each director to meet the time commitment required for membership on the particular committee, and the extent to which there
should be a policy of periodic rotation of committee members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee
also oversees the process of evaluations of the Board, its committees and executive management of the Corporation, and make recommendations
to the Board as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Term Limits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has not adopted term limits
for directors of the Corporation. The Board believes that the need to have experienced directors who are familiar with the business
of the Corporation must be balanced with the need for renewal, fresh perspectives and a healthy skepticism when assessing management
and its recommendations. In addition, as mentioned above the Board undertakes an assessment process that evaluates its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While term limits can help ensure the Board
gains fresh perspective, imposing this restriction means the Board would lose the contributions of longer serving directors who
have developed a deeper knowledge and understanding of the Corporation over time. The Board believes that term limits have the
disadvantage of losing the contribution of directors who have been able to develop, over a period of time, increasing insight into
the Corporation and its operations and thereby provide an increasing contribution to the Board as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board and Senior Management Diversity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation believes that an effectively
functioning Board is critical to its success, and that its Board must have the flexibility to adopt director election and composition
practices that suit its unique needs and circumstances. The Corporation seeks the most qualified persons, regardless of gender
or other characteristics unrelated to expertise and performance. Accordingly, the Corporation does not have written policies or
set targets with respect to representation of women on the Board or as members of its senior management team. Such policies, while
well intended, may create arbitrary and technical impediments to the selection of the most qualified persons. This approach enables
the Corporation to make decisions regarding the composition of its Board and senior management team based on what is in the best
interests of the Corporation and its shareholders. The Corporation has no female executive officer and there are no women on the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Short-Selling</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Corporation&rsquo;s Insider
Trading Policy, which is applicable to its directors, officers and other employees, no such person may engage in short-selling
of the Corporation&rsquo;s securities or any trading in exchange-traded options with respect to the Corporation&rsquo;s securities.
Any director or executive officer who wishes to enter into another type of hedging arrangement must consult with the Compliance
Officer as legal restrictions and/or public disclosures may be required. In addition, margin loans using the Corporation&rsquo;s
securities and other pledges of such securities present the risk that the pledgee will foreclose and sell the securities at a time
when the Corporation&rsquo;s personnel are prohibited from trading, with possibly serious collateral consequences. For this reason,
such an arrangement may be risky and should not be undertaken without the prior written approval of the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is responsible for establishing
director and executive officer compensation and reviews such compensation at least as often as annually. The Board believes that
directors should be fairly compensated for undertaking the responsibilities associated with serving as a director. At the same
time, director compensation should be consistent with market practices generally. The Board delegates to the Compensation Committee
responsibility for periodically assessing market practices for director and executive officer compensation. In addition, the Compensation
Committee evaluates director compensation in the context of evaluating director recruitment and retention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee operates under
a written charter adopted by the Board. The Compensation Committee is currently composed entirely of independent directors: Mr.
Brughera (Chair), Mr. Rallis and Dr. Islam. The Compensation Committee held seven meetings in the fiscal year ending December 31,
2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to director compensation, the
Compensation Committee of the Board determines the compensation to be paid to Fennec&rsquo;s executive officers and periodically
reviews Fennec&rsquo;s compensation structure to ensure that Fennec continues to attract and retain qualified and experienced individuals
to Fennec&rsquo;s management team and motivate these individuals to perform to the best of their ability and in Fennec&rsquo;s
best interests. Among other things, the Compensation Committee considers compensation levels of comparable positions in similarly
sized organizations in the biotechnology industry. The Compensation Committee also administers the Stock Option Plan and approves
new stock option grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has created audit, compensation,
and the governance and nominating committees to ensure that the Board functions independently of management. It is also customary
practice for directors (i) to regularly receive detailed information describing Fennec&rsquo;s performance, and (ii) when necessary,
to speak directly with management regarding additional information required on particular matters of interest. Moreover, directors
have access to information independent of management through Fennec&rsquo;s external auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the Board, the Audit Committee
of the Board retains, oversees and evaluates Fennec&rsquo;s independent auditors, reviews the financial reports and other financial
information provided by Fennec, including audited financial statements, and discusses the adequacy of disclosure with management
and the auditors. The Audit Committee also reviews the performance of the independent auditors in the annual audit and in assignments
unrelated to the audit, assesses the independence of the auditors, and reviews their fees. The Audit Committee is also responsible
for reviewing Fennec&rsquo;s internal controls over financial reporting and disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee operates under a written
charter adopted by the Board. Multilateral Instrument 52-110 &ndash; Audit Committees requires certain disclosures be cross-referenced
with respect to the Audit Committee when soliciting proxies from Shareholders for the purpose of electing directors. The Corporation
is relying on the exemption found in Part 7 of the Multilateral Instrument applicable to U.S. Listed Issuers. The Audit Committee
met four times during the fiscal year ended December 31, 2017. As required by the rules of the SEC and Canadian securities laws,
the Audit Committee is composed entirely of independent directors, each of whom the Board has determined is &ldquo;financially
literate&rdquo; for purposes of the applicable laws: Mr. Rallis (Chair), Mr. Haigh and Dr. Islam. In addition, the Board has determined
that Mr. Rallis qualifies as an &ldquo;audit committee financial expert,&rdquo; as defined in Item 407(d)(5) of Regulation S-K
promulgated by the SEC. A copy of the Corporation&rsquo;s Audit Committee Charter is included as Schedule &ldquo;A-2&rdquo; to
this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee has (1)&nbsp;reviewed
and discussed the audited financial statements with management, (2)&nbsp;discussed with Haskell &amp; White LLP, our independent
registered public accounting firm, the matters required to be discussed by PCAOB Auditing Standard No.&nbsp;1301 (&ldquo;AS 1301&rdquo;),
and (3)&nbsp;received the written disclosures and the letter from Haskell &amp; White LLP required by the Independence Standards
Board Standard No.&nbsp;1, and has discussed their independence with the independent registered public accounting firm. Based
upon these discussions and reviews, the Audit Committee recommended to the Board that the audited financial statements be included
in the Corporation&rsquo;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2017 that we filed with the
SEC on March 28, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Haskell &amp; White LLP served as our independent
registered public accounting firm and audited our consolidated financial statements for the year ended December&nbsp;31, 2017.
Though the Audit Committee does not have formal pre-approval policies and procedures in place, it has pre-approved all of the services
performed by Haskell &amp; White LLP as discussed below, as required by SEC regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the aggregate
fees for professional services and other services rendered by our independent auditors, Haskell &amp; White LLP in fiscal year
2017 and Deloitte LLP in fiscal year 2016 (in US dollars):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal&nbsp;Year<BR> Ended 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal&nbsp;Year<BR> Ended 2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">Audit Fees<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">138,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">65,602</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Audit-Related Fees<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Tax Fees<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,026</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All Other Fees<SUP>(4)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">152,066</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">77,298</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><I>Audit Fees</I> include fees for the standard audit work that needs to be performed each year
in order to issue an opinion on the consolidated financial statements of the Corporation.&nbsp;It also includes fees for services
that can only be provided by the Corporation&rsquo;s auditor such as auditing of non-recurring transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><I>Audit-Related Fees</I> include fees assurance and related services that are reasonably related
to the performance of the audit or review and are traditionally performed by the independent accountant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Tax Fees include fees for periodic tax consultations and compliance services in various local,
regional and national tax jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">All Other Fees include fees for products and services other than Audit Fees, Audit Related Fees
and Tax Fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee does not have formal
pre-approval policies and procedures; however, prior to the engagement by the registrant, the Audit Committee approved all of the
services performed by Haskell &amp; White LLP as required by SEC regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Submitted By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE
AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Chris A. Rallis,
Chair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Adrian J. Haigh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Dr. Khalid
Islam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Governance and Nominating Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee
of the Board develops, recommends and oversees the effectiveness of Fennec&rsquo;s corporate governance guidelines. In addition,
the Governance and Nominating Committee oversees the orientation and education of directors and the process of evaluating the Board
and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee
of the Board is charged with nominating activities, including determining desired Board skills and attributes for directors, conducting
appropriate and necessary evaluations of the backgrounds and qualifications of possible director candidates, and recommending director
nominees for approval by the Board or the Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance and Nominating Committee
is currently composed three independent directors: Mr. Haigh (Chair), Mr. Brughera and Dr. Islam. The Governance and Nominating
Committee held five meetings in the fiscal year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Retention of Outside Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fennec&rsquo;s Corporate Governance Guidelines
provide that the Board, each Board committee, the Chairman and the Lead Independent Director, on behalf of the independent directors
as a group, shall have the authority to hire legal, accounting, financial or other advisors as they may deem necessary in their
best judgment, without the need to obtain the prior approval of any officer of the Corporation. The Corporation will arrange for
payment of the invoices of any such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2017, Fennec became subject
to Section&nbsp;16(a) of the Exchange Act. Section&nbsp;16(a) of the Exchange Act requires our directors, certain officers, and
persons who beneficially own more than 10% of our Common Shares to file with the SEC initial reports of ownership and reports of
changes in ownership of our Common Shares and other equity securities. Officers, directors and beneficial owners of more than 10%
of our Common Shares are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To our knowledge, based solely on our review
of the copies of such reports furnished to us, and except as disclosed in the following paragraph, our officers, directors and
beneficial owners of more than 10% of our Common Shares complied with all Section&nbsp;16(a) filing requirements during fiscal
2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joint filers Manchester Management PR,
LLC, Manchester Management Company, LLC, Manchester Explorer, L.P., James E. Besser and Morgan C. Frank filed a late Form 3 report
of initial ownership and a late Form 4 reporting six change of ownership transactions that occurred between October 18, 2017 and
October 24, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-variant: small-caps"><B>SHAREHOLDER
PROPOSALS FOR NEXT YEAR&rsquo;S ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BCBCA permits certain eligible shareholders
of the Corporation to submit shareholder proposals to the Corporation, which proposals may be included in a management proxy circular
relating to an annual meeting of shareholders. Shareholders having proposals that they desire to present at the next year&rsquo;s
annual meeting of shareholders should, if they desire that such proposals be included in the Corporation&rsquo;s proxy circular
relating to such meeting, submit such proposals in time to be received by Fennec not later than February 28, 2019. To be so included,
all such submissions must comply with the requirements of the SEC&rsquo;s Rule 14a-8 and you should pay close attention to that
rule. Proposals should be mailed to the Secretary at Fennec Pharmaceuticals Inc., PO Box 13628, 68 TW Alexander Drive, Research
Triangle Park, NC 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>ADDITIONAL
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial information for the financial
year ended December 31, 2017 is provided in the Corporation&rsquo;s consolidated financial statements and management&rsquo;s discussion
and analysis (&ldquo;<B>MD&amp;A</B>&rdquo;), which are included in the Annual Report. Security holders who wish to be added to
the mailing list for the annual and interim financial statements and MD&amp;A should complete the appropriate sections of the proxy
or contact the undersigned at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation&rsquo;s Annual Report on
Form 10-K for the fiscal period ended December 31, 2017 (including the consolidated financial statements and MD&amp;A) and other
information relating to the Corporation is available on SEDAR at <U>www.sedar.com</U> and at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPROVAL OF THE BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contents of this Circular and its sending
to Shareholders have been approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DATED</B> at Research Triangle Park,
North Carolina this 30<SUP>th</SUP> day of April, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>BY ORDER OF THE BOARD OF DIRECTORS</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>/s/ Rostislav Raykov</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rostislav Raykov</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A-1&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mandate of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify"><B>Responsibilities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of Fennec Pharmaceuticals Inc. (the &ldquo;<B>Company</B>&rdquo;) is responsible for the stewardship of the Company. All directors
shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill
that a reasonably prudent person would exercise in comparable circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board retains plenary authority and
power to do all lawful acts and things as are not by law or otherwise directed or required to be exercised or done by the shareholders
of the Company or in some other manner. In carrying out its responsibilities, the Board of Directors (or the committees of the
Board of Directors duly constituted by the Board of Directors to the extent such delegation is permitted by law and is specifically
made by the Board of Directors) shall have the following specific responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the adoption of a corporate strategic plan that includes the periodic review and approval of business
plans, which take into account, among other things, the opportunities and risks of the business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the identification of the principal risks of the Company&rsquo;s business and ensuring the implementation
of appropriate systems to manage these risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the adoption of processes for succession planning, the periodic review of succession plans for
key members of senior management, including the Chief Executive Officer (the &ldquo;<B>CEO</B>&rdquo;), and the appointment and
training of, and monitoring the performance and compensation of senior management, including officers of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">the adoption of a communications policy and the periodic review of such policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">the establishment of adequate systems of internal controls and management information systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">the adoption of corporate governance guidelines or principles applicable to the Company, including
with respect to: (i) the size and composition of the Board; (ii) the orientation of new directors; (iii) the provision of continuing
education to directors; (iv) the compensation and tenure of directors; (v) the periodic assessment (at least annually) of the performance
of the Board, its committees and directors, this Mandate, the Charter for each committee of the Board; and (vi) the position description(s)
applicable to each individual director, as well as the competencies and skills each individual director is expected to bring to
the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">the oversight of the maintenance by management of practices and processes to ensure compliance
with applicable laws and appropriate ethical standards, including the adoption by management of corporate policies and procedures
and the adoption of a written code of business conduct and ethics applicable to directors, officers and employees of the Company
containing standards that are reasonably designed to deter wrongdoing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">to the extent feasible, satisfying itself as to the integrity of the CEO and other senior officers
and that the CEO and other senior officers create a culture of integrity throughout the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">the submission of matters or questions requiring the approval of shareholders to the shareholders
for approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">the approval of the submission to the shareholders of any amendment to the articles of the Company
or the approval of any adoption, amendment or repeal of any articles or bylaws of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">the recommendation of candidates for election or appointment to the Board of Directors, including
the review of nominations recommended by shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">the approval of the annual objectives of the Company and the Chief Executive Officer, and the assessment
of the performance of the Company and the Chief Executive Officer against the approved objectives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">the approval of an annual operating budget for the Company and its subsidiaries on a consolidated
basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">the authorization of the issuance of securities of the Company as required in accordance with applicable
laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">the declaration of dividends on shares of the Company or the approval of the purchase, redemption
or other acquisition of shares issued by the Company as required in accordance with applicable laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">the oversight of the reliability and integrity of accounting principles and practices followed
by management, financial statements and other financial reporting, and disclosure practices followed by management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">the oversight of the qualifications and independence of the independent auditors of the Company
and the approval of the terms of their audit and non-audit service engagements as required in accordance with applicable laws and
the requirements of any stock exchanges on which the Company lists its securities and of securities regulatory authorities, as
adopted or in force or amended from time to time, and the assessment of the performance of the independent auditors, the filling
of a vacancy in the office of the independent auditor between shareholders' meetings, and the recommendation of the annual appointment
or, if appropriate, the removal, of the independent auditors of the Company to the shareholders of the Company for their approval
in accordance with applicable laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">the approval of the annual audited consolidated financial statements of the Company and, as required
in accordance with applicable laws, the approval of the quarterly unaudited consolidated financial statements of the Company and
overview of the accounting principles and practices followed by management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">the approval of prospectuses, annual information forms, annual reports on Form 20-F, 40-F or 10-K
or other applicable form, as the case may be, and proxy circulars and proxy statements sent to shareholders of the Company and
the review of managements' discussion and analyses of financial condition and results of operations, and other material disclosure
documents as determined by the Board of Directors from time to time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">the establishment and periodic review of the Company&rsquo;s measures for receiving feedback from
security holders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify">the development of clear position descriptions for directors, including the Chair of the Board,
a &ldquo;Lead Independent Director&rdquo; and the chair of each board committee; and, together with the CEO, a clear position description
for the CEO, which includes delineating management&rsquo;s responsibilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify">the oversight of the management of environmental risks and practices, charitable activities and
other social responsibility matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify">to the extent not otherwise referred to above, the review and approval of all proposed
                                                           transactions and matters described below under the heading &ldquo;B. Decisions Requiring Prior Approval of the Board&rdquo;
                                                           and, where applicable, in accordance with the requirements of the <I>Canada Business Corporations Act</I>, the stock
                                                           exchanges on which the Company lists its securities and securities regulatory authorities, as adopted or in force or amended
                                                           from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In discharging its duties and responsibilities,
the Board of Directors is expected to be fully diligent in its oversight to avoid fraud or abuse. Accordingly, the Board may conduct
such examinations, investigations or inquiries, and engage such special legal, accounting or other advisors, at the expense of
the Company, at such time or times and on such terms and conditions as the Board of Directors considers appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">B.<BR></TD><TD STYLE="text-align: justify"><B>Decisions
Requiring Prior Approval of the Board</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to such other approvals as
required by applicable law or the stock exchanges on which the Company lists its securities and securities regulatory authorities,
the Board (or the committees of the Board duly constituted by the Board to the extent such delegation is permitted by law and is
specifically made by the Board of Directors) shall review and approve:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the strategic plan, financial plans and operating budget of the Company on at least an annual basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the quarterly and annual financial statements of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">all material capital expenditures not part of the approved operating budget, all mergers and acquisitions,
and all material investments and dispositions of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">all material borrowings and banking arrangements of the
Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">all financing by the Company including the issuance of debt, equity and derivative instruments;
for greater certainty, this includes the approval of all off-balance sheet financings by the Company or by special purpose entities
or affiliates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">the purchase and redemption of securities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">any changes to the articles or by-laws of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.</TD><TD STYLE="text-align: justify">the hiring and, if necessary, the termination of the Chief Executive Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55pt"></TD><TD STYLE="width: 35.45pt">9.</TD><TD STYLE="text-align: justify">the compensation paid to senior management and directors, including the issuance of stock options
and non &ndash; arm&rsquo;s length consulting arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55pt"></TD><TD STYLE="width: 35.45pt">10</TD><TD STYLE="text-align: justify">any other material matters outside the ordinary course of the Company's business including all
major strategic and policy decisions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">any other matter specified by the Board as requiring
its approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Expectations of Management</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CEO, through the Senior management,
is responsible for the day-to-day operations of the Company and for providing the Board, directly or through the Chair of the Board,
the appropriate committee or the Lead Independent Director, with timely, complete and accurate information on such operations.
The Board expects management to propose and, after Board approval, implement the Company's strategic plan and to be accountable
for the Company's financial and competitive performance. The Board expects the Company's resources to be managed in a manner consistent
with enhancing the value of the Company and with consideration for ethics and corporate social responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may request that certain members
of senior management attend all or any portion of a Board or committee meeting and may schedule presentations by managers who can
provide additional insight based on their personal involvement in the matter or their particular expertise. Each director shall
have complete access to any member of senior management. The Chief Financial Officer and the General Counsel of the Company shall
each have access to meet separately with the Audit Committee and Governance Committee respectively, the Chairman and Lead Independent
Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may reasonably rely on the information
provided to them by the Company&rsquo;s senior management personnel and outside advisors and auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Measures for Receiving Shareholder Feedback</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The Company has developed a Disclosure Policy to facilitate consistent disclosure practices aimed at informative, timely and broad
dissemination of material information to the market in compliance with applicable securities laws and the rules and policies of
any exchange on which the Company&rsquo;s securities are listed. The Disclosure Policy Committee established under the Disclosure
Policy is responsible for overseeing and monitoring communications with, and responses to inquiries from, both institutional and
individual investors and the financial community consistent with the objectives of the Company&rsquo;s Disclosure Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company spokespersons as appointed by the
Disclosure Policy Committee from time to time are available to shareholders by telephone, fax and e-mail and the Company maintains
up-to-date material of interest to shareholders and investors on the Company&rsquo;s web site at www.Fennecpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>E.</B></TD><TD STYLE="text-align: justify"><B>General.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors shall review and
assess the adequacy of the mandate of the Board on an annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Mandate is intended, or
may be construed, to impose on any member of the Board a standard of care or diligence that is in any way more onerous or extensive
than the standard required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A-2&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FENNEC PHARMACEUTICALS INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Audit Committee Charter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of the Audit Committee (the
&ldquo;Committee&rdquo;) of the Board of Directors (the &ldquo;Board&rdquo;) of Fennec Pharmaceuticals Inc. (together with its
subsidiaries, the &ldquo;Company&rdquo;) is to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assist the Board in fulfilling its responsibility to oversee the
Company&rsquo;s accounting and financial reporting processes and audits of the Company&rsquo;s financial statements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Review the financial reports and other financial information provided
by the Company, the Company&rsquo;s disclosure controls and procedures, and its internal accounting and financial controls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assume direct responsibility for the appointment, compensation, retention
(and where appropriate, replacement), and oversight of the work of the outside auditor in preparing or issuing an audit report
or related work;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Oversee the independence of the outside auditor and approve all auditing
services and permitted non-audit services provided by the outside auditor;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Receive direct reports from the outside auditor and resolve any disagreements
between management and the outside auditor regarding financial reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Carry out the specific responsibilities set forth below in furtherance
of this stated purpose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Committee Membership and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Resources and Authority</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In discharging its oversight role, the
Committee is granted all responsibilities and authority required by MI 52-110 and SEC Rule 10A-3, including without limitation
the authority to investigate any matter brought to its attention with full access to all books, records, facilities and personnel
of the Company and the authority to engage independent legal, accounting or other advisors to obtain such advice and assistance
as the Committee determines necessary to carry out its duties. The Committee may request any officer or employee of the Company
or the Company's outside counsel to attend a meeting of the Committee or to meet with any member of, or consultants to, the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall provide the Committee
all appropriate funding, as determined by the Committee, for payment of compensation to any such advisors and any outside auditor,
as well as for any ordinary administrative expenses of the Committee that it determines are necessary or appropriate in carrying
out its responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Responsibilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee&rsquo;s role is one of oversight,
and it is recognized that the Company&rsquo;s management is responsible for preparing the Company&rsquo;s financial statements
and that the outside auditor is ultimately accountable to the Board and the Committee, as representatives of the stockholders,
and is responsible for auditing those financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following functions shall be the common
recurring activities of the Committee in carrying out its oversight role. The functions are set forth as a guide and may be varied
and supplemented from time to time as appropriate under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Appointment of Outside Auditor. The Committee
shall have direct responsibility for the appointment, compensation, retention (and where appropriate, replacement), and oversight
of the work of any registered public accounting firm selected to be the Company&rsquo;s outside auditor for the purpose of preparing
or issuing an audit report or performing other audit, review or attest services for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Appointment and Performance Evaluation
of Chief Financial Officer and Internal Auditor. The Chair of the Committee shall participate in the identification of candidates
for the positions of Chief Financial Officer and Lead of the Company&rsquo;s internal auditing function, if any, and shall advise
management with respect to the decision to hire a particular candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disclosure Controls and Procedures. The
Committee shall review periodically with management the quality and adequacy of the Company&rsquo;s disclosure controls and procedures.
The Committee must be satisfied that adequate procedures are in place for the review of the Company&rsquo;s public disclosure of
financial information extracted or derived from the Company&rsquo;s financial statements and must periodically assess the adequacy
of those procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internal Controls. The Committee shall
discuss periodically with management and the outside auditor the quality and adequacy of the Company&rsquo;s internal controls
and internal auditing procedures, if any, including any significant deficiencies in the design or operation of those controls which
could adversely affect the Company&rsquo;s ability to record, process, summarize and report financial data and any fraud, whether
or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal controls,
and discuss with the outside auditor how the Company&rsquo;s financial systems and controls compare with industry practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Policies. The Committee shall
review periodically with management and the outside auditor the quality, as well as acceptability, of the Company&rsquo;s accounting
policies, and discuss with the outside auditor how the Company&rsquo;s accounting policies compare with those in the industry and
all alternative treatments of financial information within U.S. and Canadian generally accepted accounting principles that have
been discussed with management, the ramifications of use of such alternative disclosures and treatments and the treatment preferred
by the outside auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-approval of All Audit Services and
Permitted Non-Audit Services. The Committee shall approve, in advance, all audit services and all permitted non-audit services
to be provided to the Company by the outside auditor; provided that any non-audit services performed pursuant to an exception to
the pre-approval requirement permitted under applicable laws shall not be deemed unauthorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Audit. In connection with the annual
audit of the Company&rsquo;s financial statements, the Committee shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">request from the outside auditor a formal written statement delineating
all relationships between the auditor and the Company consistent with Independence Standards Board Standard No. 1 and such other
requirements as may be established by the Public Company Accounting Oversight Board, discuss with the outside auditor any such
disclosed relationships and their impact on the outside auditor&rsquo;s objectivity and independence, and take appropriate action
to oversee the independence of the outside auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approve the selection and the terms of the engagement of the outside
auditor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">review
with management and the outside auditor the audited financial statements to be included in the Company&rsquo;s Annual Report filed
on the System for Electronic Document Analysis and Retrieval (&ldquo;SEDAR&rdquo;) and with the SEC, and review and consider with
the outside auditor the matters required to be discussed by AS No. 1301.</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor any press releases
in respect of the audited financial statements before the Company first publicly discloses this information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">perform the procedures set forth below in &ldquo;Financial Reporting
Procedures&rdquo; with respect to the annual financial statements to be reported.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor the Company&rsquo;s
critical accounting policies and practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recommend to the Board whether, based on the reviews and discussions
referred to above, the annual financial statements should be included in the Company&rsquo;s Annual Report filed on SEDAR and with
the SEC.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interim Reports. In connection with the
Company&rsquo;s preparation of its interim financial information to be included in the Company&rsquo;s Quarterly Reports filed
on SEDAR and filed with the SEC, the Committee shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">review
with the outside auditor the Company&rsquo;s interim financial information and the matters required to be discussed by AS No.
1301.</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">perform the procedures set forth below in &ldquo;Financial Reporting
Procedures&rdquo; with respect to the interim financial information to be reported.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">by action of a majority of the Committee or through the Committee
Chair, review with the outside auditor, prior to filing, the Company&rsquo;s interim financial information to be included in the
Company&rsquo;s Interim Reports filed on SEDAR and filed with the SEC.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">by action of a majority of the Committee or through the Committee
Chair, review with the outside auditor any interim press releases in respect of the interim financial statements before the Company
first publicly discloses this information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Reporting Procedures. In connection
with the Committee&rsquo;s review of each reporting of the Company&rsquo;s annual or interim financial information, the Committee
shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">discuss with the outside auditor whether all material correcting
adjustments identified by the outside auditor in accordance with U.S. and Canadian generally accepted accounting principles and
the rules of the SEC and CSA are reflected in the Company&rsquo;s financial statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with the outside auditor all material communications between
the outside auditor and management, such as any management letter or schedule of unadjusted differences.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review with management and the outside auditor any material financial
or other arrangements of the Company which do not appear on the Company&rsquo;s financial statements and any transactions or courses
of dealing with third parties that are significant in size or involve terms or other aspects that differ from those that would
likely be negotiated with independent parties, and which arrangements or transactions are relevant to an understanding of the Company&rsquo;s
financial statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">resolve any disagreements between management and the outside auditor
regarding financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hiring Policies. The Committee shall review
and approve the Company&rsquo;s hiring policies regarding partners, employees and former partners and employees of the present
and any former outside auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Charter. The Committee shall review and
reassess at least annually the adequacy of this Charter and recommend any proposed changes to the Board for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reports. The Committee shall report its
activities to the full Board on a regular basis and make such recommendations to the Board with respect to the above and other
matters as the Committee deems necessary or appropriate. The Committee shall also prepare and submit to the appropriate authority
or body any other report required by applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Complaint Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any issue of significant financial misconduct
shall be brought to the attention of the Committee for its consideration. In this connection, the Committee shall establish procedures
for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls
or auditing matters and (ii) the confidential, anonymous submission by employees of the Company of concerns regarding questionable
accounting or auditing matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INSTRUMENT OF PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Annual and Special Meeting of
Shareholders of Common Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fennec Pharmaceuticals Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To be held on June 7, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned holder of Common Shares
of Fennec Pharmaceuticals Inc. (the &ldquo;Corporation&rdquo;) hereby appoints (with full power of appointment and substitution),
Chris Rallis, Board Member, or failing him, Rostislav Raykov, Chief Executive Officer and Board Member of the Corporation, or in
place or stead of the foregoing Robert Andrade, Chief Financial Officer of the Corporation or ______________________________ as
Proxy of the undersigned to attend the Annual and Special Meeting of the Corporation (the &ldquo;<B>Meeting</B>&rdquo;) to be held
at the Omni Hotels &amp; Resorts Berkshire Place in the Sutton Room, 21E 52<SUP>nd</SUP> Street, New York, New York, USA at 10:00
am EDT on June 7, 2018 and at any adjournment thereof. The undersigned hereby revokes any instrument of proxy heretofore given
to attend and vote at the Meeting. Without limiting the general power hereby conferred, the person above named is directed to vote
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">To vote as follows <B>(and in each case, if no specification is made, to vote FOR)</B>:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Khalid Islam (Chair)</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Adrian Haigh</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Chris A. Rallis</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Marco Brughera</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Rostislav Raykov</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To vote FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or WITHHOLD VOTE FROM </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the resolution appointing Haskell &amp; White LLP as the auditors of the Corporation for the ensuing year and authorizing the directors of the Corporation to fix their remuneration <B>(and, if no specification is made, to vote FOR)</B>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To vote FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or AGAINST </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the advisory vote on executive compensation resolution <B>(and, if no specification is made, to vote FOR)</B>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To vote FOR </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or AGAINST </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the resolution approving the extension of certain outstanding options held by certain of the Corporation&rsquo;s officers and directors <B>(and, if no specification is made, to vote FOR)</B>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the discretion of the said Proxy holder, to vote upon any amendments or variation of the above matter or any other matter that may be properly brought before the said Meeting or any adjournment thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>This Proxy is solicited on behalf of the Management of the
    Corporation and will be voted as directed in the space provided above or, if no direction is given, it will be voted FOR each
    resolution. The persons named in this Proxy are officers of the Corporation. Each shareholder has the right to appoint a person,
    who need not be a shareholder, to attend and to act for him and on his behalf at the Meeting, other than the persons designated
    above. To exercise such rights, the names of the persons designated by Management to act should be crossed out and the name
    of the shareholder&rsquo;s appointee should be legibly printed in the blank space provided.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>DATED this <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> , 2018</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Signature of Shareholder</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Shareholder&rsquo;s Name (Please Print)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">In the event that the date is not completed, this Proxy will be deemed to be dated upon the day
that it is mailed by the Corporation to the securityholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">This Proxy will not be valid and will not be acted upon or voted unless it is signed and delivered
to the attention of Computershare Trust Company of Canada, 100 University Avenue, 8<SUP>th</SUP> Floor, Toronto, Ontario, M5J 2Y1,
no later than 48 hours prior to the Meeting time or delivered to the Chairman at the Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">In addition to any revocation in any other manner permitted by law, a Proxy may be revoked by instrument
in writing executed by the securityholder or his attorney duly authorized in writing or, if the securityholder is a company, under
its corporate seal by an officer or attorney thereof duly authorized and deposited either at the registered office of the Corporation,
c/o Mr. Rostislav Raykov at any time up to and including 4:30 p.m. on the last Business Day preceding the day of the Meeting, or
any adjournment thereof, at which the Proxy is to be used, or with the Chairman at the Meeting on the date of the Meeting, or any
adjournment thereof and upon such deposit, the Proxy is revoked.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The signature on the Proxy should be exactly the same as the name in which the shares are registered.
If the appointee is a corporation, the Proxy must be exercised under its corporate seal or signed by an officer or attorney duly
authorized. Persons signing as executors, administrators, trustees, etc. should so indicate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-variant: small-caps">FENNEC
PHARMACEUTICALS INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(the &ldquo;Corporation&rdquo;)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NI
51-102 Request Form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO REGISTERED HOLDERS AND BENEFICIAL
OWNERS OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">National Instrument 51-102 requires that
the Corporation send annually to the registered holders and beneficial owners of its securities a request form to allow the securityholders
to elect to receive a copy of the Corporation&rsquo;s financial statements. If you wish to receive the Corporation&rsquo;s financial
statements or other selective securityholder communications, please complete and return this form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please note that this request form will
be mailed each year and both registered and beneficial securityholders must return this form each year to remain on the Corporation&rsquo;s
distribution list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PLEASE RETURN TO:</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-variant: small-caps">Fennec
Pharmaceuticals Inc.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: left; text-indent: 0in">c/o Computershare Trust
Company of Canada,</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: left; text-indent: 0in">100 University Avenue, 8<SUP>th</SUP> Floor,</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: left; text-indent: 0in">Toronto, Ontario, M5J 2Y1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned security holder of the
Corporation hereby elects to receive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%; border: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 89%; text-align: justify"><FONT STYLE="font-size: 10pt">Annual financial statements and MD&amp;A of the Corporation, or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interim financial statements and MD&amp;A of the Corporation, or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(C)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Both (A) and (B) as described above.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>NAME: </B>(Please print)</FONT></TD>
    <TD STYLE="width: 60%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>ADDRESS:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>(REQUIRED)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>SIGNATURE:</B></FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><B>DATE:</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I certify that I am a securityholder of the Corporation</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Canadian Securities Administration
recognizes that developments in information technology allow companies to disseminate documents to securityholders and investors
in a more timely and cost efficient manner than by traditional paper methods. By providing an e-mail address, you will be deemed
to be consenting to the electronic delivery to you at such e-mail address of the interim financial statements and reports, if electronic
delivery is allowed by applicable regulatory rules and policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>E:MAIL (optional):</B></FONT></TD>
    <TD STYLE="width: 60%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv493448_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv493448_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!R@*+ P$1  (1 0,1 ?_$ /$  0 " @,! 0$
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M\C@#L*$\S17H]I^1P!V%">9HKT>T_(X ["A/,T5Z/:?D< =A0GF:*]'M/R.
M.PH3S-%>CVGY' '84)YFBO1[3\C@#L*$\S17H]I^1P!V%">9HKT>T_(X ["A
M/,T5Z/:?D< =A0GF:*]'M/R. .PH3S-%>CVGY' '84)YFBO1[3\C@#L*$\S1
M7H]I^1P!V%">9HKT>T_(X ["A/,T5Z/:?D< =A0GF:*]'M/R. .PH3S-%>CV
MGY' '84)YFBO1[3\C@#L*$\S17H]I^1P!V%">9HKT>T_(X ["A/,T5Z/:?D<
M =A0GF:*]'M/R. .PH3S-%>CVGY' '84)YFBO1[3\C@#L*$\S17H]I^1P!V%
M">9HKT>T_(X ["A/,T5Z/:?D< =A0GF:*]'M/R. .PH3S-%>CVGY' '84)YF
MBO1[3\C@#L*$\S17H]I^1P!V%">9HKT>T_(X ["A/,T5Z/:?D< =A0GF:*]'
MM/R. .PH3S-%>CVGY' '84)YFBO1[3\C@#L*$\S17H]I^1P!V%">9HKT>T_(
MX! .R8KMKH=F1_0[_P#4=#Q-MT>H[@^,=3T>KX=5U_T^C\G3\/R^' )/1/W/
MKW[.2_"-@$MP!@# & , 8 P!@# & , IV3WOKJ/M4_2VCR>L]AIY6!KLSI-0
MM-T3I':C,)&/;VQY68B3:0\F\C#%=)L#G[0,T.1<$.J.0Y@.F/,7J%:"UW/1
M-I-8TMN1SF8UE$5J&G)RSW:(9,TY"0EH6KL(Y6>[)BV:R9WCM=NBV9]<F5<Z
M9E4RF QTIS0:1@]=;#VG-6]>+J.HEG;?:QG59M@V'6Z\>Q;RCY.YTU"#7MT&
M#:*=)/.FJRZI1DJ1RF8[<Y%3 6.OLJAM=;J[?7M,2GK)&EFV(I=!7$80M(+"
M]XQL@."D$QHT83_>0,!1,*?R!Q\& 4__ (OM"'C]22;>S65^VWQ!2-FU 2*U
M;M:7?7V!B(5*R24G"Q<72G<F"+2NKIOQ*NBBH9H<%2E$OAP"W=<[.H&W*9%[
M#UM;(>X4N9([%A8(AQUC,RD<[782;1R14J+F/D8J0:JMW;9P1)PU<)'35(0Y
M3% #KU/:U ONN(W;E(L2%NU[,PRU@B+%7&LA+I2L2W,N19S',F31:2>'34;*
M%%)-$RHG()0*(^# *QH/-SR][+=:V:5._&4/N2+D)K4JT_4[M3&.RX^):>/R
M*E'D;E6X%A97+./ 7)V[511R#8IENKZHHG #-*\R^E6TGMV(?7!6,?:')"FV
MN65K-MC&]3/9F3>1K#8SU]!-V4V^LS%VBI'MXU1XN\!9,J1#'.0I@,_4=UT"
MY2MC@&3N<@[#3X&*M%H@KK4[/1I*$KDXM,H0\X[):XF)04BWYZ\]Z*R*BI""
MV4*H)#$,4 (S$\SFFYD:BY;6.0;UW8,JQ@J!>92KV>'U]=YF5!88:-K-WDXE
MI7)):PB@8(HP. 2ES=$&)W G)T@)32]VZQV#==@:WJ]E!Q?]6*PY+[39.(G:
M[8Z^A8FRKRORAXJPQD6ZD(&<;MU#-)%H5PP<"F<I%A,0Q0 D-*V!6-A-YMU5
MG$DZ0KMCF*E+FD:_8*^+>PU]VHPF8]).P1D8H][/>I&2.L@"K<Q@'HG-\N 0
M:P<PNKZ]+VV%/)3D\[U\5 ^Q%*;3[7=&5!!Q'$F$T;:^J\/*MHF0"&4(\.S$
MQGJ3-0BYT2HJ)G,!U['S*:9K"VKD7=L<RX[L;.G>IEJ95K?L!I?T&4$M:'1Z
MX]HT#86;SJJTW4?_ 'Y>DT(94O2* B $]HFQ:KLAC,/ZJXEE"5^?=U><:3M7
MM%/EXJ>8LX^0<1[V#M\/!S"(BPE6RZ:G4=2LBN0Z9S%'C@' RV?2Y6[RNO(:
M46F[37@;A:&T+&R<I&U)=XQ&381]JGF;16"@)E_'B1=%@Y<IO5$%4U02ZM0A
MS 8.E[TU;L*="NU*T)2D@Y93<I"J#'RK*-MD169A"OV29I4P_9-HJXQ$#.ND
MFKMS&K.445%DA,;H+)&.!]V3>.K:?M+7VE[1:DX/9&UVEC>:X@)"+FT4;B2H
M,"2EF;0T]V:-=6DH:.5(NLT,[(ZZLX&*F8!P#[V'NW6&J[#K6I7JTI0]IW#9
M7=1UG7D8V9F)BWV".BUYN19QK&$CI%=-&-BFYEW+E<$FK<G#K%"B8H"!C+#O
M_6E>G+1732$[8)2B(,W5_1I5/M=W3HB+]CVJS+;%ZK#RR42_7B>#PK(PB_\
M$SD7ZGJ3D.8#KK<R6D$)S4L"IL&)Z_?")E=.2Z;:47J&Q50B%Y\D=6;R@P5I
MCV;<PS8[ENP%^5ZY2*(HI*<!X 96Z;QUOKZ9D("URDTQE(RJ&NKI!G2[M.IF
MKI99C @Y9.8"O2;:3?+3<DW:),6QU7ZRZQ"D1-QP"$1O-IH^5L$Y5F<U<^W:
MM:*E2[6R=:AV^P+4[1?$8ES3XFU/'U%;L:XK8&T\R504>*HH]4Z3.8Y2F <
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M$PW,U&<S&OK%&UA.:INX5Z=L2Y679[J190C"YUV?I&\6[>O2!I5Z[0=)2;5
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M+;_U1N%2N6^B-91HWC.8?3I-3:@DIC3=H<D4,@QN$4<57].E' ",7+<4%/\
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M#.+CA-.J$*H@8#T$P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P"N_UY_$3^7> 9>B?N?7OV<E^$; *_Y@=SMM#Z
M]"\N( ]A,YM5-IS-NM+-:W ,)&ZV./K;"9N5M?-WC*GTV*<R!59"2517*W2#
MP)G.8I1 UXB^<^R6R,@F% T<O;MCO(K<-FF:LGLB$CZHC3],VYC1Y2S5'8:D
M&Y:79A=[#)HHUHQ&#-%^!'!G"K,C<QA Z[3GRA9Y@UO]0UG-S>C(Z0T="WO9
MCRQ14/+5.9WW&4B7K;=E13-7SFQ,JFQV7 GL*P/VAV7CB@-TGAFRP !OY@#
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MWAGD%%62UV*\S+1U8K+8@>6VW2CF;M$[UUFF)APW=STP\5=.02.1-1=0Q^B
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M-'^S@&HW./9)'7&L73'3S*FQ^X9EG+S]/)8(M%U'.X_7[="T6").@*1B>,W
MB#>N-5!X>+NYM)QP$$3!@$<M/-#KMG2];7F@:=_O%AMG\O-^YCH-5K+UNO$:
MU37#+7\I8H61-)@JLC8>S[^D5)($Q)XXV405,E])0@'U#\SE!E9U*HKZ75B+
M?99S44;K2(?RE?.UM\9NBF7J^5>6EI2/(])5%8JNZPGUI1J*;Y1#Q),$#.3.
M$R@!'93FWJ"$5).(/EYD)J;J]-YAK/>H):>J,0-7D>5^Z5ZG;2K9)!P9=*:<
MJGL*;N%<MR>+R*!DNL%MTSBB!/'?,1KH]T@ZG7M2+V%*9V%KK7 N".(.,FFT
MCLC6".W(NS$K;[H+O*+&5584WDBFOTBR**Z":*@-UE2 8'F/D7M2W_RYU.O-
M;D-6N],Y@Y.UU+6D36',]8'U B:!(UA9F:<:]-NLS6G'1."+A$JYEB%4 P%*
M)0)%';/@H"T1.J(_5MYVW*UF:UW3-CW%&KH]KUJ3V+"MYZ'F+.A$03:LF9P,
M1*QZ]@<E<L!:(NA71;+ 10A *H;\Z%&"C/+Y*<NTM'1J^C76]ZJQ3G::_DK'
M78.]PE!M,4N5%=-G"2L9(V5BX:]:LHF^;*G\**B9DQ L-QS%U5G*V*CNM%N0
MVS"[#M-$8T*/<)6%*:3K6L:=MWMYO.UF"FE4&KRJ7^)1,F+(PMI1R*"ANI(9
MU@$UH&UX/9DI'HU?0-B+$LYVLU+9"D^2O5ZTZKM5EUG%;//&V>GR#HKE=O68
M^Q1<?*J-G!W",D_*1!!RBDNLF!K)S03.VH?>>Q*#HT+.[L[7E.BMB:HHU;J5
M1GJ\_P!SN-G6&LPY[FI88H6[&E2S=BV;RAG+]HW09@LNB=-P4IQ EM7VO*4S
M=FR:CL*C=YJS*\P>H-2L99E(001.LI_8G+SK:U(P<%"KMF\S,UEW?7[TRJQS
M LV*_(H K%*H5$#,J<UU(1"P-#:(7<3T,OH8$H&/GZD]6,CO[:DSJ" 92DJ4
MZ< QL=7M,./;#1JZD&S=)4O5NU5"+$3 YU^91%A9$ZI+<L#V/F&VU*/I6?1"
MY41XG#[$V+J:$VA6F::S551*3@D3S18Y^]3,4S<Q>O21<%$2% ^#<UM";U"B
MW&2T>M',;)+-*]8&BLW5W#^%L/\ ?F?0,Y%5YHR\9<VXE:MB!WKIX=.-8C$F
M14(L9TL5H $S6W]1$:TZV)_<Z[=ZK>.W\#3[S&JPK\UCN2.VXC2\+57591 )
M^*=W"V2X+1:J*3XAX]LLHY!LN";94#'DY@ZZT67CK)R]6*J3*-*Y@KDDRGFJ
M42C+,]!*4=1RZ@CS,5%2;ZO7J.OS1:*?JLVYBJ(.$7""1T_I 59*\P+&VPNU
M)%76S^I4JEON421K\U0[+!--A2">]I.@30,Y=.9@7T(RBBA9DV$F@B991>-(
MY*BH"RZ9D0+]_O:@WD9:[97-%.K/KVO$VVP:V^/F:3'E>6?3MM&CSL+*1T_)
M1!8%C-V%C)%CGYG"Z0MXI=5T1J!VX+ 4<OO.+NEWTK(5BIR<7'0^Z^836>R*
M/6T&$^AL%;7&@KI>XE*O*KQD6_G6SYZUCG47Q3CU#N3=6<@EX&$#9_15UUWO
MZCN[C URKMHX))6&*:%F&4VY:.R14:\?L)= T;$S52M< ^D%&3^*DV35\S=-
MC")#)'24.!I)I[F3E('EZU+.6S6C[=5]M.D]\;OG;"I*4JK%4A-)7J&AY^.4
M3,Q8MDI!2%M+3Q B#4$EE41(J9/I'7*!N!2]GU/9%@00H6H%[%3&EFB*?;+@
M5Q7V#BHS<UJ^(VJV<R%;?+I.WL TBK+%,'3ANN=TG)R!")M56Z:SE,#8SN94
M_9Z)_0T?[. :']S;)_BT_N7':%Q"M&Y;U-J]82.HQ52W,=NA!%4(D-1.4($D
M,;Q0&(F$O4!Q$_7?CL K?3?,S$5'6\8KNND24V#F Y@+? ;",O 2TI<"ZQYB
M2:N)4UJ_'-FSJ,? %ZK[2,7. INR%5ZPJ)D@ZT#<6H2KO85,V4LRU &MKO57
MUAKM:#8,'((52PR2->:2M;MT4Z>Q4#,2M)<.Y--!T=1DS<).6KI'H#U9%5 -
M1>7C>=1B6-PCN9J1M6K]LZCUG!RF[-6;<KL"J@654F2PJNVM/VJJ0Q([86N;
MQ8%^SHUO#JN 1<F;- 9M7:HHJ@<W)WLJ^;#?.H'95-/)VP9>>I>R:\LYK#:3
MTW<M>NY8UGM<U%I,(QS7JGM!E8X U3A6XR2I&2(NS+CUSD4@(=ROW7;]D/K*
M[V,LS;=2)5OFA?<PEIO-4JT;7H-77NSYJ"U"MKB3C(:#E)*>5AH)XC*MT"NX
M\S-'KEA1==7UP%G['K]XJIN5B0=WBSQ$CO+F$KE5N]::,ZLE'5^KV356U+P\
MJ,.#NN/'[96*GJ\T3!T98RX)-^J*)2"("!%+Y:[/H_>+>J[KE;A Z9L,EI^N
M::W]%UNIS>MSV SR-;7+7_,6TC($[NG7+9,TN+*.G5D6L,9!XW(V68NR* N!
MF=KR-JU5S%I:J>W7K-?\T32"@M97%ZQK977+#L-!Q)H/(=44ZX+:39[?8HG+
M2S3)G/66:.68'ZUN<A  NKF?G#:KK^CJE3&4<QL&ZM\ZWT6-[DXJ-E'E5B["
MRGINQ6@C=XS/$O+0[@JFY9QOC"!FI95ZBJ=%4A!0.!F[>S@M#/X>0EY65O[#
M9EDH6J->4BRI09W26RYV0G55I'O<G$(/T(:2@TC.7Q7(.P9I11A9I"=7J#@4
M])<V-11*_BX;E]>3%SKR/,,WM];4G:S$M:_/<MYJ6ZML6G./$A2EF=DK]Z8R
M,,[10 JZ*R97";505"I =LG-145$Q!/E[DSOI*7Y;DZG&A-4T'$W6.:)S.QF
MO;!(*G=%9P3Z/F:V[1E(\5'!FZ8)JI*K%.(% Y(?FDJ$ZC9(&/T([-MK7D)M
M>P[,U>K+U\CFO1^H9R(@Y<D#92MSQ%K>6T9ULXKX #-%VW.(NU6)R] 0#OF2
MU#>6%VAJE6%62(Z,?;9@))M+0M+V7,4F:U1&;!A+YKFO6N)%M+Q($GBQQ)1N
MH_3BI]J=%^V23*0RH&"JW,K6V4F_AIK6"+NN-*5RKIT"6<OAG[[=KCS"1,RY
M8-+2PA*R*+95LE#**O%V*+DW!HNLFBH*Z;=,#:"GL&NY-;(R:]'M.CYQS.OH
MV1CY*#8LK2R3JML68O%X=2:BCIJU^Y,8H5&#]1FDNK%OB*]4W7'HI :F:=NR
M4!K9YM+8MBG[Q(/N97<7+E4Z4_:5%",L$PMS-3VI-2(F=M8",4B7<)%PZ"3M
M\*ARJ-3.EU45U^J* $YA]^-;7N.CZ@B]-0D.]<7[<6MML*RDRW,]J4YK.ETR
M[Q[FHJM8@[6RQ%FJVPHN4;.E0:*E24\75;IK J"0%<:BYB(VKZ*Y;)395-4O
M,M?:EI[O+>7<A7DIJ4F=I[$2UHV>LJ\T:B[EE8&6>-G<RLJG&,D&CI(&RKAP
M86Q0)/SD71AJ#8^A%#2%UK6N)BO\P<YLMEJVJ1=DLS^,UUKIK:HJ081J]<L+
MX581R"JQO%TP(H3Z*P'3#@ 'U1MRS]0T=I4FR]=PVZ>8*Y::L6VY.(T]'-92
M/L]5K#J"*A(PCRIQ4U7G=CL;"XPR+<K;J(-W*+K=6[;M>J.($DKF_P"/=6VP
MQ%GTG&Q,+_B8I?+U55V[]N-@0/<M,5/:[29N$&_C68QCUEWA%!VT254.V.8$
M@%0R)U#@?D%S'PEMFZK7ZERZO9M_/PVUK%*'/8Z;%M*]":;W:?2=R>*K2*R)
MY%0LAT9)HBD0%'#0PD^BL428!+M ;LJ.\):-BG6F5*&>RZ/U=OZHJ24C7IWM
M:D;-[4;H(2!(83%A9R&DHHQ%$!,N15!5-0JA3]8BD!M9W,J?L]$_H:/]G '<
MRI^ST3^AH_V< =S*G[/1/Z&C_9P!W,J?L]$_H:/]G '<RI^ST3^AH_V< =S*
MG[/1/Z&C_9P!W,J?L]$_H:/]G '<RI^ST3^AH_V< =S*G[/1/Z&C_9P!W,J?
ML]$_H:/]G '<RI^ST3^AH_V< =S*G[/1/Z&C_9P!W,J?L]$_H:/]G '<RI^S
MT3^AH_V< =S*G[/1/Z&C_9P!W,J?L]$_H:/]G .TRK5?C7)'C"'CVCI,IRD7
M;MDTU2E4+T3@4Y0 0 Q1X#_1@$7_ %Y_$3^7> 9>B?N?7OV<E^$; );@# &
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M1ZBL\,FDD*AU%$$#I@3DFJ:@GMEQNLJ4IW]=41KK99V,S(C%&J#*;=6)M'A
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MZ4E"W2W[#[1=;%N+E[WQOFNQU=:YPKE66%5)S*U554.!!*1!TL9PB5-4$S$
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MYJ1J:PN4X\]HK\=-G8D<"1,7!&AGW5@<2EZ8%X\ X\, GF , 8 P!@# & ,
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MT6S(>*V.F56?;=NQ]H\7FJ_$R:/>:((S3B;%U3UHL3MV+)'-P;/.'C" ()]
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M+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X
M['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[
M![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>U
MSOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]
M$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-
MY+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X
M ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q
M[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>
MUSOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[
M]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$
M-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2
MX ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .
MQ[![7._1$-Y+@#L>P>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P
M>USOT1#>2X ['L'M<[]$0WDN .Q[![7._1$-Y+@#L>P>USOT1#>2X!BIU1Y6
M828LDW=UV,+7XJ0FY=ZK$PQ4F<7%-%G[]TH/BO@3;M$#G,/W R];V]:[N(6M
MNG*O5G&$4M;E)I)=UM%JM6IVU&=Q6>%&G%RD^916+?<2/('X656LVY;AS+<[
MMBD'3"9W#?9&I5%PJQ9.%TZE#N6T@]32(Z1.1!LF(1L> )\"]**,7YO!.7&.
MXHY)891P_LI?S-A;1J5</959)Q3?3])/^L1$W#*C4S6\S+?*Z7\[=UW"GCR4
MXO%I='D0^ >R?8]@]KG?HB&\ER!R7AV/8/:YWZ(AO)< =CV#VN=^B(;R7 '8
M]@]KG?HB&\EP!V/8/:YWZ(AO)< =CV#VN=^B(;R7 .VRCI=NY(J[L+B00*4X
M&:J1T:W(<3%X%,*K9 BQ13'P\ '@/SX!%_UY_$3^7> 9>B?N?7OV<E^$; );
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@'B1MGCS6_%@U5JU/C(Z[Y0ZO_>#;$BB5PP&
MYJFC)Y--<@_BA4[9=UUL8H\1X-5R_,(9/V2_Y-X-7F</Q<TSNMV-/D?9>-#1
M\%5I?"B0[FG^9^)]MEJ\:PRJEVL^5=IHE^,Z2[C/;?(!)B& , 8 P!@# & 5
MW^O/XB?R[P#+T3]SZ]^SDOPC8!+< 8 P!@# & , 8 P!@# & , 8 P!@# &
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MTM7:3C%:>E4XP?7-D8\*[2M<6E[O1>+]+S"YDTW[2+>KH<Y27P4>Q>0<2P,
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MMP!VE:/9AI[PI>K< =I6CV8:>\*7JW ':5H]F&GO"EZMP!VE:/9AI[PI>K<
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M P!@# & , KO]>?Q$_EW@&7HG[GU[]G)?A&P"6X P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MX-BWS95TTP>)GU[CKC8D1KQKJZ9U7*R<+W)6B)V3=)SW2$SP4V*'BIDP=>,
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M_4I#R3 '?:L><_J4AY)@#OM6/.?U*0\DP!WVK'G/ZE(>28 [[5CSG]2D/),
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M^I2'DF .^U8\Y_4I#R3 '?:L><_J4AY)@#OM6/.?U*0\DP!WVK'G/ZE(>28
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & >),@8>:?XO,;'@;M#7
MW)?21?K 4YA9]_U@26 W >*8/T;1/MBC\XC C_H^"?J:^Y_!.53R<SSZXP7/
MV*T=YTX2_/=)#M3_ #+Q4C#RK'**.+YNUU]]3DOS?0>VV0"3$, 8 P!@# &
M, 8 P!@%=_KS^(G\N\ R]$_<^O?LY+\(V 2W & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M^NR'E> .Y-8\V?79#RO '<FL>;/KLAY7@#N36/-GUV0\KP!W)K'FSZ[(>5X
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO5'! %!(;@!:F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M98 [-M'M.T]WDO66 .S;1[3M/=Y+UE@#LVT>T[3W>2]98 [-M'M.T]WDO66
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M3RIW$C*T)+6[:RB>J:FQ90Z;:255M#=P2PO&1R/E5BJL:NB[ZLY"B)7*B(>
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M,%M]'BI0I]<'SG$<+LIK6V2U,\OL7F.8U75DWKV,7L_&;E/JDN8]6\ALDX8
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MN23Q<4VU'%X%F=W<5**H3FW23QP_AI?1S&P.:<QQ@# & , 8!7?Z\_B)_+O
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M4TH+Y;'99)0\J<ZLNC5X%X3\'X;G.GN #FYEOB#7E2/<CTW=4U6WEF$.<#B
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M&&.BJD!P . <2]3K1,W$?E\!P_KQ]M<,J?D97=3ZY/\ #6//.<ECJH3?=_\
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MFS%+&4FV\%AB^=O6^DV!)+S"9"IITV4(F0H$(0DA6RD(4H<"E*4LP %*4 X
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MJQ+L5)>/;D*[6 I$EB%*"R@   <_$"<8 P!@# & , 8 P!@# & , 8 P!@#
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M!@# & , 8 P!@# & , 8!7?Z\_B)_+O ,O1/W/KW[.2_"-@$MP!@# & , 8
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MMEZ[SQN*C9Z)-8MM:NA+5W>\>V6J.67E]T:BFEJ;3U!HZR9>CVI$5YD,^J'
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MB_O_ )3A&%]*XI+V->,:ORFNT^6<7F/#7<[,<92M%1J/EI2=/Y*>Q\DUG/\
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MCAAWGHY,-)9N=,7Q@# & , 8!7?Z\_B)_+O ,O1/W/KW[.2_"-@$MP!@# &
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MYS:U[:KC[.#BG[V7DR73%M$CY;G&5YO2[?++BE7I^XDFUUK7'J:3+/S4&R&
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M'CP_IXY@SX#\)Z[QMZM:FW[2[B_QE,T%QPTWCMOUC*,VI==M<+PTSMI\H7+
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M*6Z^[]'R+2CW5M?C8G)WG&[BU?K"XS_,4G[2IV7^Z4"\H'E\T+5@3"M:3U+
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MZC479_(+R?;>%TO<-#49.3=E."LW56"E(FA4/\JYY"HK0JKE?CX>*W6@(_*
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MY/:KU3M,OC0:JB5/%MI\O/,-K9V0>#A-U6XI^DB(> WADI*M.S  _=0+Q_\
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M , 8 P!@# & , 8 P!@# *[_ %Y_$3^7> 9>B?N?7OV<E^$; );@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MXE&RQ))RM2O4-GTK&/8F?C1.9!5NZ5$JB*J*Q4EDCIE NO & , 8 P!@# &
M4YMC>E%TPXHK2XELJKC85SK5'@BUZKS4^W:R=JLL'4HU]8I)@U/%5J$">LC)
M [EZNB!CKE*D"A^)< P]FYAZI3=H5K6-EJNR(@MOL4?3*]L1U3W)-8R5VEX)
MW8HNIM[-XSXRI(OX]@L1-P5H,;XX06AG0.OQ. 1Z]<T])UU,;G0L$+:75=T;
M5JC,6R=K$'*VM^\LULC+%9"4>%K,#'O9-W+Q%.AVLJ\7.9-JW:RC<RITR HH
M4#N[%YG:7K6C5[9DK5-FS.OIBH-M@3%OJ]./+PU%I+AO'/#V*Y*F?M5VR#-C
M) X7;,4W[]-NBLKU IIF-@&QI#%.4IR"!B'*!BF#P@8I@ 2B _<$!P#ZP!@#
M & , 8 P!@&O-9YF=?70NXPJ<1L6==:2?Q<;9(IIKZRH3=@=3<*A.1(T>%D&
M;.4LS*1;+@5!T1)-JJ("H104/QP@=!CS2T![J#;>W7$3;ZXAI$]KC]B4FX0Q
M(&[0-DJU?86<:TLP*[?QSN0GH>9CUHY1HZ=-GA)!#JU#"82@!FZIS!5>P[.B
M]*R$+:8#:*^LS[(FXEW!2BE7A2,#TUM8*RVO2K)G 62>@'EZ8%7)'F7(0BH&
M4%,P@3 .[K_F!USLW9^V]2U%U+/K-I4U:2N3Q6)<-JZJYLRMA:)M:]-J#XM/
M+PLK57[&2ZD!*S?ME&YA%5-0I +MP!@# & , 8 P!@%/;RWE1N7J@R6Q]@EL
MJL#& H99O5*O-6R7.1NV7?/' L89JX!FPCX]HJX<NW1V[1!),1.J41*!@,'M
M3F(JFG9F#96^J[)&N2SJK,I/8\13G,CKNH.KK9$:C64;18 <HK(&?S[I!%7Q
M-N]!@1PDL[\714*H(':N&]Z_3=CK:_>Q$T_+#ZO>[2MTS#1\C-J5Z-<6J/J%
M*A4*]"1TG.ST]?I;M0&#=JD8_1AU_ 83$# *]7YR-<JT/2%\KE0VM=4^8,)4
MVN:K5J<BO<G!8.!D[),#,P\K,1#>%&.C(A852K..D"@ 0 $P\, VGBWII*-C
MI$S)]&&D&+1Z:-E$DT)*/,Z;IKBRD4$5G"2+YH*G5K$*H<I5"B &,'A$#O8
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MWB)=W6U456N0E&*PO$7+4RP3]7GG,U5[5+5QY$L&LS75DOQPD< *B?21*)C
M4"?Z6V[6]ZZZAMFU*.L<7 3CRP,6C2UQ9(>9*M6K%*U>2.JT1=OVYVIY2'6%
MNNDLJBX0Z*J9C$.41 M3 & , 8!7?Z\_B)_+O ,O1/W/KW[.2_"-@$MP!@#
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M6OMXJE&K$!;+FN=RLM9K!%1#1G*S!W#WB_=B]>(G/USC_>%@'K%?QAC8!9N
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M[0U/K1BWB*)?8YVF7;<@X3@KJFRF:JRE)JEC#QKUVV>QC9\E)*-P;-3*+*
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MB$^0>5[MIUY?9,:HG_CYC^<Q=8E9=$$\&T\3*MKY,HS1^KE%2-AZ,EQ%(AC
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M CQ H* 5; :+VYR_J;VWV]&$O%BWWK?85MYAJ/56TJ^='VQ7V#XNEHS3[9O
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M7&[4;8,EMZXPSR/0DM8U&OP-4L= ;T9]$ V5M-4Z#MZ@\4629.>M3*<Z?5&
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M1@#[:, ?;1@#[:, ?;1@#[:, ?;1@#[:, ?;1@&!_P#SG_\ TK_Q[_\ KO\
,P+__ #W_ /KL __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
